----item----
version: 1
id: {12ACDAB0-C49D-402F-A2D0-C0211065231D}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/VC Funding 2012
parent: {D5B965D3-AC3D-4A7F-90E6-65193022C6B5}
name: VC Funding 2012
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: bd2e500a-e7be-40d3-9649-40593e2ad062

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 93812

<p>  <tbody> <tr> </tr> <tr> <td> <tbody> <tr> <td>Are you betting on medtech's hottest areas?<a></a><br> <em>By Tina Tan, Editor</em><br> Find out who's investing in what with Clinica's venture/growth financing table, updated regularly with the latest investment deals.  </td> </tr> <tr> <td><a><b>VC Funding 2013</b></a></td> <td><b>VC Funding 2012</b></td> <td><b><a>VC Funding 2011</a></b></td> <td><b><a>FREE TRIAL</a></b></td> </tr> </tbody> </td> </tr> <tr> <td><a></a></td> <td><div><a></a></div></td> <td><a></a></td> <td><div><a></a></div></td> <td><a></a></td> <td><a></a></td> <td><a></a></td> <td><a></a></td> </tr> <tr> <td><div><a>Deals</a></div></td> <td><div><a>M&amp;A </a></div></td> <td><div><a>Financials</a></div></td> <td><div><a>Funding </a></div></td> <td><div><a>Legal</a></div></td> <td><div><a>Start-ups &amp; SMEs </a></div></td> <td><div><a>Market Monitor </a></div></td> <td><div><a>Google Map: M&amp;A 2010 </a></div></td> </tr> </tbody>  <p> <p>  <tr> <th><b>Company</b></th> <th><b>Sector</b></th> <th><b>Technology</b></th> <th><b>Investors</b></th> <th><b>Amount raised</b></th> <th><b>Financing round</b></th> <th><b>Total raised by company</b></th> <th><b>Month</b></th> </tr> <tr> <td><p><b>Active Implants </b></p></td> <td><p>Orthopaedics</p></td> <td><p>Active Implants is developing the TriboFit Buffer hip implant, and the NUsurface meniscus knee implant</p></td> <td><p>Undisclosed</p></td> <td><p>$10.0m</p></td> <td><p>Series C</p></td> <td><p>At least $24.0m</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>AirXpanders </b></p></td> <td><p>Surgical</p></td> <td><p>AirXpanders is a tissue-expansion company focused on the area of breast cancer reconstruction</p></td> <td><p>Vivo Ventures; GBS Venture Partners; Prolog Ventures; Heron Capital; WTI </p></td> <td><p>$10.0m </p></td> <td><p>Series D</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Aria Diagnostics</b></p></td> <td><p>IVD</p></td> <td><p>Aria Diagnostics is developing prenatal tests based on the directed analysis of cell-free DNA in maternal blood. The company's primary focus is on the detection of foetal trisomies such as Trisomy 21, associated with Down's syndrome</p></td> <td><p>Meritech Capital Partners; Venrock; Domain Associates</p></td> <td><p>$52.7m</p></td> <td><p>Series C</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Avinger </b></p></td> <td><p>Cardiovascular / peripheral vascular</p></td> <td><p>Avinger is developing next-generation catheter-based technologies for the treatment of peripheral artery disease</p></td> <td><p>Undisclosed</p></td> <td><p>$22.5m</p></td> <td><p>Series C</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Carticept Medical </b></p></td> <td><p>Orthopaedics</p></td> <td><p>Carticept Medical is developing and commercialising products for the treatment of osteoarthritis or cartilage damage. Its Navigator Delivery System is a computer-controlled, infusion system to automate and improve the efficiency of fluid or medication administration, and the Cartiva Synthetic Cartilage Implant is designed to replace or repair worn or damaged cartilage</p></td> <td><p>Domain Associates; New Enterprise Associates; SonoSite</p></td> <td><p>$10.0m</p></td> <td><p>Series C</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Clearside Biomedical </b></p></td> <td><p>Drug delivery / Ophthalmology</p></td> <td><p>Clearside is developing a micro-needle to administer drugs to the back of the eye and retina</p></td> <td><p>Undisclosed </p></td> <td><p>$4.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>ConforMIS </b></p></td> <td><p>Orthopaedics</p></td> <td><p>ConforMIS is developing and commercialising medical devices for osteoarthritis treatment and joint damage</p></td> <td><p>AGC Equity Partners; Axel Johnson</p></td> <td><p>$89.0m</p></td> <td><p>Series E</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Corinthian Ophthalmic </b></p></td> <td><p>Drug delivery / Ophthalmology</p></td> <td><p>Corinthian is developing new delivery methods to administer drugs to the eye</p></td> <td><p>Undisclosed </p></td> <td><p>$3.25m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>CytoPherx </b></p></td> <td><p>Inflammation</p></td> <td><p>CytoPherx is developing and commercialising a cytopheresis system, which is used to sequester and deactivate leukocytes in patient with kidney injury</p></td> <td><p>Early Stage Partners; ONSET Ventures; Capital Midwest Fund</p></td> <td><p>$34.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Glysure </b></p></td> <td><p>Patient monitoring</p></td> <td><p>Glysure is developing in-hospital continuous blood glucose monitoring systems</p></td> <td><p>Morningside Venture; Amadeus Capital Partners; Chester Investments; Delta Partners</p></td> <td><p>$10.9m</p></td> <td><p>Series C</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>InCytu </b></p></td> <td><p>Biomaterials</p></td> <td><p>InCytu is developing Cellarium, a biopolymer scaffold to accelerate healing and enhance tissue regeneration</p></td> <td><p>Undisclosed </p></td> <td><p>$1.86m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>KeraNetics </b></p></td> <td><p>Biomaterials</p></td> <td><p>KeraNetics uses purifed keratin proteins for use in therapeutic and research applications</p></td> <td><p>Undisclosed </p></td> <td><p>$4.7m (of a planned $7.0m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>LensAR</b></p></td> <td>  <p>Ophthalmology</p></td> <td><p>LensAR is focused on the development and commercialisation of a next-generation laser and 3D-imaging technology for use in refractive cataract surgery</p></td> <td><p>Aisling Capital; Florida Growth Fund</p></td> <td><p>$24.05m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>MC10 </b></p></td> <td><p>Medical electronics</p></td> <td><p>MC10 is developing its conformal electronics platform for use in medical equipment and devices</p></td> <td><p>Aberdare Ventures</p></td> <td><p>$2.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Mevion Medical Systems </b></p></td> <td><p>Oncology</p></td> <td><p>Mevion Medical Systems is a radiation therapy company focused on the treatment of cancer</p></td> <td><p>ProQuest Investments; Caxton Heath Life Sciences; Venrock; CHL Medical Partners</p></td> <td><p>$45.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Natera</b></p></td> <td><p>IVD</p></td> <td><p>Natera develops tests for preimplantation genetic diagnosis performed during in-vitro fertilisation</p></td> <td><p>Lightspeed Venture Partners; Claremont Creek Ventures; Sequoia Capital</p></td> <td><p>$20.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>NeuroLogica </b></p></td> <td><p>Imaging</p></td> <td><p>NeuroLogica is developing BodyTom, a portable computed tomography imaging system  </p></td> <td><p>Gordon Charitable Remainder Trust</p></td> <td><p>$12.0m </p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Oxford Cancer Biomarkers </b></p></td> <td><p>Biomarkers / Personalised medicine / Cancer</p></td> <td><p>Oxford Cancer Biomarkers is focused on the development and commercialisation of predictive cancer biomarkers</p></td> <td><p>Quintiles</p></td> <td><p>&pound;3.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>ProteoMediX </b></p></td> <td><p>IVD / Cancer</p></td> <td><p>ProteoMedix is developing biomarker diagnostics for the detection of prostate cancer</p></td> <td><p>Altos Venture; BioValley Business Angels Club; Zurcher Kantonalbank</p></td> <td><p>CHF2.6m</p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>SEA Medical Systems </b></p></td> <td><p>Patient monitoring</p></td> <td><p>SEA Medical is developing devices to identify drugs, concentrations, and diluents in IV fluids, and measure flow rates and cumulative dose during IV administration</p></td> <td><p>JK&amp;B Capital</p></td> <td><p>$3.0m </p></td> <td><p>Series B</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Solx</b></p></td> <td>  <p>Ophthalmology</p></td> <td><p>Solx is focused on the management and surgical treatment of glaucoma</p></td> <td><p>Undisclosed </p></td> <td><p>$3.25m (of a planned $9.0m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>SPR Therapeutics </b></p></td> <td><p>Neurology</p></td> <td><p>SPR Therapeutics is developing its Smartpatch and MicroPulse Neurostimulation pain-relief devices</p></td> <td><p>NDI Medical; JumpStart </p></td> <td><p>$2.2m (of a planned $2.5m financing round)</p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>ALung Technologies </b></p></td> <td><p>Respiratory </p></td> <td><p>ALung is developing the Hemolung Respiratory Assist device, to remove the need to keep patients in respiratory distress sedated on mechanical ventilators</p></td> <td><p>Undisclosed</p></td> <td><p>$10.0m</p></td> <td><p>Series B</p></td> <td><p>At least $25.0m</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Apollo Endosurgery </b></p></td> <td><p>Surgical</p></td> <td><p>Apollo Endosurgery develops therautic endoscopy devices such as its OverStitch Endoscopic Suturing System and FlexShears Endoscopic Scissors </p></td> <td><p>Novo AS; Remeditex Ventures; CPMG; PTV Sciences; HIG BioVentures</p></td> <td><p>$47.6m</p></td> <td><p>undisclosed</p></td> <td><p>At Least $59.1m</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>CardioInsight Technologies </b></p></td> <td><p>Imaging / <br> Cardiovascular / peripheral vascular</p></td> <td><p>CardioInsight is commercialising its ECVUE 3D cardiac mapping system </p></td> <td><p>Undisclosed</p></td> <td><p>$7.5m</p></td> <td><p>Series C</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>CartiHeal</b></p></td> <td><p>Orthopaedics</p></td> <td><p>CartiHeal is developing its Agili-C cartilage regeneration device for use in arthroscopic procedures</p></td> <td><p>Accelmed; Access Medical Ventures</p></td> <td><p>$5.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Cayenne Medical </b></p></td> <td><p>Orthopaedics</p></td> <td><p>Cayanne Medical is commercialising its AperFix II, CrossFix II and iFix systems for the treatment of sport-related orthopaedic injuries</p></td> <td><p>Undisclosed</p></td> <td><p>$10.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Cervilenz </b></p></td> <td><p>Reproductive medicine</p></td> <td><p>Cervilenz is developing a disposable medical device that measures cervical length to help identify and manage pregnant women at high risk for preterm birth</p></td> <td><p>Undisclosed</p></td> <td><p>$2.0m (of a planned $3.0m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>At least $6.0m</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Checkpoint Surgical </b></p></td> <td><p>Surgical</p></td> <td><p>Checkpoint is developing the CHECKPOINT Stimulator/Locator, a single-use, sterile device intended to locate and identify nerves and to test nerve and muscle excitability</p></td> <td><p>Undisclosed</p></td> <td><p>$1.7m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Dymedix Diagnostics </b></p></td> <td><p>Patient monitoring</p></td> <td><p>Dymedix is focused on the development of sleep sensors for use in clinical sleep studies</p></td> <td><p>Undisclosed</p></td> <td><p>$2.15m (of a planned $4.2m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>GeneWeave Biosciences </b></p></td> <td><p>IVD</p></td> <td><p>GeneWeave is developing its GeneScout platform for the detection of pathogens</p></td> <td><p>Decheng Capital; Claremont Creek Ventures; X/Seed Capital</p></td> <td><p>$12.0m </p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Integrated Diagnostics</b></p></td> <td><p>IVD</p></td> <td><p>Integrated Diagnostics is developing blood-based molecular diagnostics for the early detection of cancer and Alzheimer's disease</p></td> <td><p>InterWest Partners; The Grand Duchy of Luxembourg; Wellcome Trust</p></td> <td><p>$10.0m</p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Nuclea Biotechnologies </b></p></td> <td><p>Biomarkers / IVD / Cancer</p></td> <td><p>Nuclea is a translational medicine company focused on the discovery of biomarkers and in vitro companion diagnostic assays. The company's DecisionDx platform is being used to develop diagnostics for use in therapeutic and medical imaging applications for oncology and other indications </p></td> <td><p>Undisclosed</p></td> <td><p>$3.4m</p></td> <td><p>Series B</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>On-Q-ity</b></p></td> <td><p>Personalised medicine / Cancer</p></td> <td><p>On-Q-ity is focused on the development of pesonalised diagnostics for the detection and treatment of cancer</p></td> <td><p>Atlas Ventures; Mohr Davidow Ventures; Physic Ventures</p></td> <td><p>$5.0m</p></td> <td><p>Series B</p></td> <td><p>At least $31.0m</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Sense AS </b></p></td> <td><p>Patient monitoring</p></td> <td><p>Sense AS is developing accurate, non-invasive devices for the measurement of blood pressure</p></td> <td><p>SEED Capital; Vaekstfonden</p></td> <td><p>&euro;4.5m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Sequent Medical</b></p></td> <td><p>Surgical / Neurology</p></td> <td><p>Sequent Medical is developing catheter-based neurovascular devices for the treatment of intracranial aneurysms </p></td> <td><p>Delphi Ventures; Versant Ventures; Domain Associates; US Venture Partners </p></td> <td><p>$26.04m</p></td> <td><p>Series C</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>TriVascular </b></p></td> <td><p>Surgical</p></td> <td><p>TriVascular is developing the Ovation Abdominal Stent Graft, a device to be used in endovascular aortic repair</p></td> <td><p>Undisclosed</p></td> <td><p>$7.2m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>TruTouch Technologies </b></p></td> <td><p>Patient monitoring</p></td> <td><p>TruTouch is commercialising a non-invasive biometric intoxication detection system</p></td> <td><p>iTulip; Launchpad Venture Group; Verge Fund; Jerome Capital</p></td> <td><p>$3.0m (of a planned $5.0m financing round)</p></td> <td><p>Series B</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Vascular Magnetics </b></p></td> <td><p>Drug delivery</p></td> <td><p>Vascular Magnetics is developing a magnetically-targeted drug delivery system for the treatment of peripheral artery disease</p></td> <td><p>Devon Park Bioventures</p></td> <td><p>$7.0m</p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Velomedix</b></p></td> <td><p>Cardiovascular / peripheral vascular</p></td> <td><p>Velomedix is focused on the development of mild therapeutic hypothermia systems for the protection of patients from the effects of cardiovascular insults</p></td> <td><p>Undisclosed</p></td> <td><p>$10.2m</p></td> <td><p>Series B</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Alcyone Lifesciences</b></p></td> <td><p>Neurology</p></td> <td><p>Alcyone Lifesciences is focused on developing treatments for chronic neurological conditions</p></td> <td><p>Undisclosed</p></td> <td><p>$1.86m (of a planned $2.0m financing round) </p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>BodyMedia </b></p></td> <td><p>Patient monitoring</p></td> <td><p>BodyMedia is developing its BodyMedia FIT system to monitor user's activity, calorie output and sleep patterns</p></td> <td><p>Undisclosed</p></td> <td><p>$2.73m (of a planned $10.0m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Genalyte </b></p></td> <td><p>IVD</p></td> <td><p>Genalyte is developing its Multiplex Maverick system with Microring Sensor Technology for autoimmune and immunoassay applications</p></td> <td><p>Redmile Group; Claremont Creek Ventures</p></td> <td><p>$11.8m</p></td> <td><p>Series B</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Icon Medical </b></p></td> <td><p>Cardiovascular / peripheral vascular</p></td> <td><p>Icon Medical is developing a cardiac stent</p></td> <td><p>Undisclosed</p></td> <td><p>$2.7m (of a planned $5.0m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>ImaginAb </b></p></td> <td><p>IVD</p></td> <td><p>ImaginAb is developing in vivo imaging agents for Positron Emission Tomography (PET) based on antibody fragment technology</p></td> <td><p>Cycad Group; Merieux Developpement; Momentum Biosciences; Nextech Invest; Novartis Venture Funds</p></td> <td><p>$12.5m</p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>InControl Medical </b></p></td> <td><p>Urology</p></td> <td><p>InControl is developing and commercialising InTone, a device to treat female incontinence</p></td> <td><p>Undisclosed</p></td> <td><p>$3.2m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Innovative Biosensors</b></p></td> <td><p>IVD</p></td> <td><p>Innovative Biosensors develops and manufactures rapid testing systems for the detection of pathogens</p></td> <td><p>Undisclosed</p></td> <td><p>$1.5m (of a planned $2.7m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Life Core Technologies </b></p></td> <td><p>Neurology</p></td> <td><p>Life Core is developing its EXCEL<escenic_non_breaking_space></escenic_non_breaking_space>Cerebral Cooling System, a unique single use device to induce mild cerebral hypothermia to protect patients from ischaemic and reperfusion injury effects of cardiac arrest, heart attack, stroke and traumatic brain injury</p></td> <td><p>Undisclosed</p></td> <td><p>$1.0m</p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Molecular Detection </b></p></td> <td><p>IVD</p></td> <td><p>Molecular Detection is developing and commercialising a portfolio of Detect-Ready molecular diagnostic tests for the detection of infectious diseases such as MRSA</p></td> <td><p>MentorTech Ventures; Rood Hood Ventures; Elm Spring Holdings; Mid-Atlantic Angel Group</p></td> <td><p>$1.5m</p></td> <td><p>undisclosed</p></td> <td><p>At least $6.2m</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Myoscience</b></p></td> <td><p>Aesthetic medicine</p></td> <td><p>Myoscience is developing its toxin-free focused cold therapy platform technology for the treatment of forehead wrinkles</p></td> <td><p>Accuitive Medical Ventures; American Equities Overseas; Medicis Capital Group; Nexus Medical Partners; Saratoga Ventures; Valiance Capital</p></td> <td><p>$33.0m</p></td> <td><p>Series D</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>NLT Spine </b></p></td> <td><p>Orthopaedics</p></td> <td><p>NLT Spine is developing and commercialising its PROW LIF lumbar fusion product line for treating degenarative spinal conditions</p></td> <td><p>Accelmed; Peregrine Ventures</p></td> <td><p>$5.7m</p></td> <td><p>undisclosed</p></td> <td><p>$14.5m</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>OpGen </b></p></td> <td><p>Genomics</p></td> <td><p>OpGen is a whole-genome analysis company that provides tools for sequence assembly and finishing, microbial strain comparison and species characterisation</p></td> <td><p>Harris &amp; Harris Group; Cross Creek Capital; Highland Capital Partners; Versant Ventures; jVen Capital; CHL Medical Partners</p></td> <td><p>Up to $17.0m</p></td> <td><p>undisclosed</p></td> <td><p>At least $62.6m</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Promethera Biosciences </b></p></td> <td><p>Cell therapy</p></td> <td><p>Promethera Biosciences is developing HepaStem, a cell therapy based on the use of allogeneic stem cells from healthy livers, for the treatment of a wide range of liver diseases</p></td> <td><p>Boehringer Ingelheim Venture Fund; Shire; Mitsui Global Investment; ATMI; Sambrinvest</p></td> <td><p>Euro17.0m</p></td> <td><p>Series B</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Provista Diagnostics </b></p></td> <td><p>IVD / Cancer</p></td> <td><p>Provista Diagnostics is commercialising biomarker-based diagnostic tests for the detection of breast, ovarian and lung cancer</p></td> <td><p>Undisclosed</p></td> <td><p>$4.51m (of a planned $4.95m financing round)</p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>Mar</p></td> </tr> <tr> <td><p><b>Quotient Biodiagnostics </b></p></td> <td><p>IVD / Haematology</p></td> <td><p>Quotient Biodiagnostics is focused on providing immunohaematology products to hospitals and blood banks</p></td> <td><p>Galen Partners</p></td> <td><p>$11.2m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Mar</p></td> </tr> <tr> <td><p><b>Relievant Medsystems </b></p></td> <td><p>Orthopaedics</p></td> <td><p>Relievant Medsystems is developing its Intracept Ablation System for the treatment of chronic axial low back pain</p></td> <td><p>New Enterprise Associates; Canaan Partners; Emergent Medical Partners; Morgenthaler Ventures; ONSET Ventures</p></td> <td><p>$30.0m</p></td> <td><p>Series D</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Sapheon </b></p></td> <td><p>Surgical</p></td> <td><p>Sapheon is commercialising a minimally-invasive closure system for treating varicose veins</p></td> <td><p>Undisclosed</p></td> <td><p>$1.3m (of a planned $5.0m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Sientra </b></p></td> <td><p>Biomaterials</p></td> <td><p>Sientra is commercialising its portfolio of Silimed silicone gel breast implants</p></td> <td><p>Abingworth; Clarus Ventures; OrbiMed Advisors</p></td> <td><p>$65.0m</p></td> <td><p>Series C</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Solace Therapeutics </b></p></td> <td><p>Surgical / Urology</p></td> <td><p>Solace Therapeutics is developing the AttenueX Balloon device for insertion into the bladder via a catheter, for the treatment of stress incontinence and involuntary urinary leakage</p></td> <td><p>Undisclosed</p></td> <td><p>$7.0m (of a planned $20.0m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Tepha </b></p></td> <td><p>Biomaterials</p></td> <td><p>Tepha produces absorbable polymer biomaterials for the manufacture of surgical sutures and meshes</p></td> <td><p>Undisclosed</p></td> <td><p>$11.3m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Thermedical</b></p></td> <td><p>Surgical</p></td> <td><p>Thermedical is developing a Saline Enhanced Radio Frequency ablation system for excising solid tissue cancers and treating cardiac arrhythmias</p></td> <td><p>Undisclosed</p></td> <td><p>$1.5m</p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>ViewRay </b></p></td> <td><p>Imaging</p></td> <td><p>ViewRay is focused on developing a system to deliver MRI-guided radiotherapy, providing continuous soft-tissue imaging during treatment</p></td> <td><p>Siemens Venture Capital; Aisling Capital; Fidelity Biosciences; Kearny Venture Partners; OrbiMed Advisors</p></td> <td><p>$25.0m (final tranche of a $45.0m financing round)</p></td> <td><p>Series C</p></td> <td><p>At least $60.0m</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Aggredyne</b></p></td> <td><p>IVD</p></td> <td><p>Blood platelet function testing; the first product from Aggredyne's platform is the AggreGuide A-100 laser-light scattering platelet aggregometer for analysing a patient's responsiveness to anti-platelet medication</p></td> <td><p>Undisclosed</p></td> <td><p>$3m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Aleva Neurotherapeutics</b></p></td> <td><p>Neurology</p></td> <td><p>Deep brain stimulation implants based on Aleva's microDBS technology to treat Parkinson's and other central nervous system disorders</p></td> <td><p>Banexi Ventures Partners, BioMedInvest, BB Biotech Ventures III, Initiative Capital Romandie and private investors</p></td> <td><p>CHF4m</p></td> <td><p>Series B</p></td> <td><p>&euro;12.8m</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>AlloCure</b></p></td> <td><p>Cellular therapy</p></td> <td><p>Stem cell therapy for treating kidney disease</p></td> <td><p>Lundbeckfond Ventures, SV Life Sciences, Novo</p></td> <td><p>$25m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Arterial Remodeling Technologies </b></p></td> <td><p>Cardiovascular</p></td> <td><p>Bioresorbable coronary stent</p></td> <td><p>Undisclosed</p></td> <td><p>$2.9m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Cadence Biomedical</b></p></td> <td><p>Orthopaedic/ Rehabilitation</p></td> <td><p>Kinetic orthosis medical devices that help people with severe mobility disabilities walk. The devices provide stability and movement assistance to weakened muscles without the use of powered mechanisms </p></td> <td><p>HealthTech Capital, Sand Hill Angels, Tech Coast Angel, ACE Fund, Frontier Angel Fund, WINGs, Alliance of Angels and Keiretsu Forum Northwest</p></td> <td><p>$1.1m</p></td> <td><p>Series A2</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>CyVek</b></p></td> <td><p>IVD</p></td> <td><p>An integrated test system for performing bioassays, molecular diagnostics and immunodiagnostics in drug discovery and point-of-care applications</p></td> <td><p>Undisclosed</p></td> <td><p>$3m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Good Start Genetics</b></p></td> <td><p>IVD</p></td> <td><p>Pre-conception carrier screening tests</p></td> <td><p>OrbiMed Advisors, Safeguard Scientifics, SV Life Sciences</p></td> <td><p>$14m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Imricor Medical Systems</b></p></td> <td><p>Cardiovascular</p></td> <td><p>The Vision MR EP ablation catheter is an MRI-compatible electrophysiology tool for performing cardiac ablation to treat arrhythmia. </p></td> <td><p>Undisclosed</p></td> <td><p>$4m</p></td> <td><p>Undisclosed</p></td> <td><p>$10m</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>InCellDx</b></p></td> <td><p>IVD</p></td> <td><p>Molecular diagnostic tests for detecting hepatitis, cervical cancer, breast cancer, HIV/AIDS and organ transplant rejection</p></td> <td><p>Bio-Reference Laboratories</p></td> <td><p>$6m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Inogen</b></p></td> <td><p>Respiratory/ Home care</p></td> <td><p>Inogen One is a home-based, portable oxygen therapy that is used particularly by patients suffering from chronic obstructive pulmonary disease</p></td> <td><p>Versant Ventures, Accuitive Medical Ventures, Avalon Ventures and Arboretum Ventures</p></td> <td><p>$20m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Life Core Technologies</b></p></td> <td><p>Neurovascular</p></td> <td><p>Excel Cerebral Cooling system that applies therapeutic hypothermia to reduce brain damage to patients who have suffered heart attack, stroke or traumatic brain injury</p></td> <td><p>Private and angel investors</p></td> <td><p>$1m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>MolecularMD</b></p></td> <td><p>IVD</p></td> <td><p>Companion diagnostics for targeted cancer therapies under development </p></td> <td><p>Ballast Point Ventures, Nextech Invest</p></td> <td><p>$6m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Obalon Therapeutics</b></p></td> <td><p>Bariatric surgery</p></td> <td><p>A device that occupies the gastrointestinal space to promote weight loss</p></td> <td><p>Undisclosed</p></td> <td><p>$1.5m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>OvaScience</b></p></td> <td><p>Cellular therapy</p></td> <td><p>Fertility treatment based on egg precursor cells</p></td> <td><p>General Catalyst, Bessemer Venture Partners, Longwood Fund, BBT Capiral Management Advisors, Cycad Group, Hunt BioVentures, RA Capital, unnamed large global institutional investor</p></td> <td><p>$37m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>SynGen</b></p></td> <td><p>Regenerative medicine</p></td> <td><p>SynGen-1000 stem cell harvesting system, initially targeted for use by cord blood banks</p></td> <td><p>Bay City Capial</p></td> <td><p>$5m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Vivia Biotech</b></p></td> <td><p>IVD</p></td> <td><p>Personalised medicine in haematologic cancers</p></td> <td><p>Bioanal&iacute;tica Inversiones and other public investment funds</p></td> <td><p>&euro;7.2m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>ArcDia </b></p></td> <td><p>IVD</p></td> <td><p>The mariPOC is a multianalyte point-of-care test to detect respiratory tract infections</p></td> <td><p>Lifeline Ventures, Biothom, Veraventure and other private investors</p></td> <td><p>&euro;2.7m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>AssureRx Health</b></p></td> <td><p>IVD</p></td> <td><p>GeneSightRx is a line of genetic test that measure and analyse genetic variants affecting response to psychiatric medications in individual patients</p></td> <td><p>Four Rivers Group, Claremont Creek Ventures, Sequoia Capital, Cincinnati Children's Hospital Medical Center, Mayo Clinic, CincyTech, Allos Ventures, jVen Capital and Alafi Capital </p></td> <td><p>$12.5m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>AxioMed Spine</b></p></td> <td><p>Orthopaedics</p></td> <td><p>Spinal disc implants, including the Freedom lumbar disc, to treat degenerative spinal diseases and restore spinal function</p></td> <td><p>CID Equity Partners, Early Stage Partners, Ivnestor Growth Capital, MB Venture Partners, Primus Capital Funds, Reservoir Venture Partners, Charter Oak Equity, Blue Chip and Thomas, McNerny &amp; Partners</p></td> <td><p>$5m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>ClearCount Medical Solutions</b></p></td> <td><p>OR safety</p></td> <td><p>The SmartSponge is an RFID-enabled system that allows automated counting of surgical sponges and prevent them being left inside the patient</p></td> <td><p>Draper Triangle Ventures and other investors</p></td> <td><p>$1.5m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>EndoSphere</b></p></td> <td><p>Bariatric surgery</p></td> <td><p>The Satisphere system is a device inserted into the patient endoscopically and designed to treat obesity by regulating the patient's appetite and satiety by using the body's natural physiology</p></td> <td><p>Broadline Capital, Glengary, North Coast Angel Fund, Ohio TechAngel Fund and Queen City Angels</p></td> <td><p>$3.1m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Flowonix Medical</b></p></td> <td><p>Drug delivery</p></td> <td><p>The Prometra pump is a programmable implantable drug pump</p></td> <td><p>RFT Investment Company, OmniCapital Fund, Clarus Ventures and other investors</p></td> <td><p>$25m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Healthsense</b></p></td> <td><p>Patient monitoring</p></td> <td><p>Wireless 'passive' medical devices designed for remote home monitoring of elderly patients</p></td> <td><p>Radius Ventures, Ziegler HealthVest Partners and The Ziegler Companies</p></td> <td><p>$13.7m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Inspire Medical Systems</b></p></td> <td><p>Neurology/Respiratory</p></td> <td><p>The Inspire upper airway stimulation therapy employs neurostimulation to treat moderate to severe obstructive sleep apnea</p></td> <td><p>Medtronic, TGap Ventures, Kleiner Perkins Caufield &amp; Byers, US Venture Partners, Synergy Life Science Partners and GDN Hodings</p></td> <td><p>$14.5m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>i-Optics </b></p></td> <td><p>Ophthalmology</p></td> <td><p>Eye imaging devices including the EasyScan fundus camera and the Cassini cornea topographer</p></td> <td><p>Aescap Venture, De Hoge Dennen and other family funds and private investors</p></td> <td><p>&euro;6.7m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Kona Medical</b></p></td> <td><p>Neurovascular/ Surgery</p></td> <td><p>An ultrasound-based systems for carrying out renal denervation to treat hypertension in drug-resistant patients</p></td> <td><p>Essex Woodlands, Domain Associates, Morgenthaler Ventures and BioStar Ventures</p></td> <td><p>$30m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Mitralign</b></p></td> <td><p>Cardiovascular</p></td> <td><p>Percutaneous mitral valve repair</p></td> <td><p>Forbion Capital Partners, Saints Venture Capital, Oxford Bioscience Partners, Triathlon Medical Ventures, Medtronic, Johnson &amp; Johnson Development, Orchestra Medical Venutres, Oakwood Medical Invesors, Palisade Capital Management and Giza Venture Capital</p></td> <td><p>$35m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Monteris Medial</b></p></td> <td><p>Neurosurgery</p></td> <td><p>The NeuroBlate system is an MRI-guided, laser-based neurosurgical ablation system for difficult-to-treat brain tumours</p></td> <td><p>Business Development Bank of Canada, SWMF Life Science Fund and Richardson GMP</p></td> <td><p>$9m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Neuronetics</b></p></td> <td><p>Neurology</p></td> <td><p>The NeuroStar system offers transcranial magnetic stumylation to treat major depression</p></td> <td><p>Polaris Venture Partners, Pfizer Venture Investments, Investor Growth Capital, New Leaf Venture Partners, Interwest Partners, Three Arch Partners, Quaker BioVentures and Onset Ventures</p></td> <td><p>$30m</p></td> <td><p>Series E</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Novacyt</b></p></td> <td><p>IVD</p></td> <td><p>A fully automated  liquid-based cytology system for cervical cancerscreening. The system consists of the NovaPrep processor and the NovaPrep Vial test</p></td> <td><p>Arkeon Gestion and private investors</p></td> <td><p>&euro;1.5m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>OrthoSensor</b></p></td> <td><p>Orthopaedics</p></td> <td><p>The OrthoSensor knee balancer is embedded with sensors to help surgeons better place and fit knee implants in the patient</p></td> <td><p>Ziegler Medtech Capital Advisors</p></td> <td><p>$15m</p></td> <td><p>Series B2</p></td> <td><p>$42m</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Oxford Nanopore Technologies</b></p></td> <td><p>Molecular diagnostics</p></td> <td><p>MinION is a gene sequencing device the size of a USB stick</p></td> <td><p>Existing investors</p></td> <td><p>&pound;31.4m</p></td> <td><p>Undisclosed</p></td> <td><p>&pound;105.4m</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Pathfinder Therapeutics</b></p></td> <td><p>Imaging/Surgery</p></td> <td><p>The Explorer is an image-guided surgery system used in cancer treatment procedures, such as resection or ablation</p></td> <td><p>Undisclosed</p></td> <td><p>$5.3m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Regentis Biomaterials</b></p></td> <td><p>Regenerative medicine</p></td> <td><p>Gelrin is a biodegradable hydrogel platform designed for tissue regeneration applications; GelrinC is designed to treat articular cartilage lesions </p></td> <td><p>Royal DSM, Crossroad Rund, Medica Venture Partners, SCPVitalife and the Technion Investment Opportunities Fund</p></td> <td><p>$10m</p></td> <td><p>Series C</p></td> <td><p>$18m</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Sonitus Medical</b></p></td> <td><p>ENT</p></td> <td><p>The SoundBite hearing system is a non-surgical and removable hearing device that transmits sound via the teeth</p></td> <td><p>Abingworth, Aberdare Ventures, Arboretum Ventures, In-Q-Tel, Novartis Venture Funds, RWI Ventures</p></td> <td><p>$25m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Vibrynt</b></p></td> <td><p>Bariatric surgery</p></td> <td><p>The Vibrynt Prevail implant is a device that limits the amount of food that enters the stomach by restricting expansion </p></td> <td><p>Delphi Ventures, New Enterprise Associates, Texas Pacific Group and other investors</p></td> <td><p>Around $2.75</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Zyga Technology</b></p></td> <td><p>Orthopaedics</p></td> <td><p>Minimally invasive spinal devices such as the SImmetry spinal fusion system and the Glyder facet resurfacing system to treat facetogenic pain caused by degeneration in the joints in the back of the spine</p></td> <td><p>Versant Ventures, Split Rock Partners, Domain Associates and MB Ventures</p></td> <td><p>$25m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>MedShape </b></p></td> <td><p>Orthopaedics</p></td> <td><p>MedShape is developing a range of orthopaedic devices</p></td> <td><p>GE Capital</p></td> <td><p>$3.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p><escenic_non_breaking_space></escenic_non_breaking_space></p></td> </tr> <tr> <td><p><b>Ablative Solutions</b></p></td> <td><p>Neurology</p></td> <td><p>PVRD (PeriVascular Renal Denervation) is a proprietary technique for managing drug-resistant hypertension</p></td> <td><p>BioStar Ventures, Michigan Accelerator Fund and angel investors</p></td> <td><p>$5.3m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Agendia</b></p></td> <td><p>IVD</p></td> <td><p>Symphony is a suite of tests that offer breast cancer patients more personalised medicine. It includes the MammaPrint, that tests recurrence of breast cancer, BluePrint, a molecular subtyping assay, TargetPrint, an ER/PR/HER2 expression assay and TehraPrint an alternative therapy selection assay. </p></td> <td><p>Debiopharm Group, Van Herk Group, ING Corproate Investments, Breedinvest, Gilde Healthcare, Korys and other investors</p></td> <td><p>$65m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>AliveCor</b></p></td> <td><p>Patient monitoring</p></td> <td><p>Mobile ECG device</p></td> <td><p>Burril &amp; Company, Khosla Ventures</p></td> <td><p>$10.5m</p></td> <td><p>Series B</p></td> <td><p>$13.5m</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Aptus Endosystems</b></p></td> <td><p>Cardiovascular/ Peripheral vascular</p></td> <td><p>Fortevo endograft system is used for the endovascular repair of abdominal aortic aneurysms. The HeliFX aortic securement system helps to secure the sealing and fixing of the endograft to the aortic wall</p></td> <td><p>Synergy Life Science Partners, US Venture Partners and Longitude Capital Management</p></td> <td><p>$25m</p></td> <td><p>Series BB</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Astute Mediccal</b></p></td> <td><p>IVD</p></td> <td><p>Novel protein biomarker-based tests for detecting community and hospital-acquired acute conditions. Areas of focus include acute coronary syndromes, abdominal pain, cerebrovascular injury, kidney injury and sepsis</p></td> <td><p>MPM Capital, Kaiser Permanente Ventures, De Novo Ventures, Delphi Ventures, Domain Associates and Johnson &amp; Johnson Development Corporation</p></td> <td><p>$40.4m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Auxogyn</b></p></td> <td><p>IVD</p></td> <td><p>Eeva is a noninvastive test to evaluate embryo viability during in vitro fertilisation </p></td> <td><p>SR One, GlaxoSmithKline, Kleiner Perkins Caufield and Byres, TPG Biotech and Merck Serono Ventures</p></td> <td><p>$18m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Awarepoint</b></p></td> <td><p>Healthcare IT</p></td> <td><p>aware360&deg; Suite of real-time location systems are designed to manage and track hospitals' mobile assets, patients, personnel; also for patient monitoring, and workflows across healthcare facilities </p></td> <td><p>Kleiner Perkins Caufield &amp; Byers, Cardinal Partners, Venrock, Jafco Ventures, Avalon Ventures, New Leaf Venture Partners and Top Tier Capital Partners</p></td> <td><p>$14m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Benvenue Medical</b></p></td> <td><p>Orthopaedics</p></td> <td><p>Minimally invasive devices for treating degenerative disc disease and vertebral compression fractures. Kiva and Blazer are used for the latter application, and Luna is an interbody spacer system for spinal fusion</p></td> <td><p>Versant Ventures, DeNovo Ventures, Domain Associates, Technology Partners </p></td> <td><p>$25m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>BioBehavioural Diagnostics</b></p></td> <td><p>Neurology/ Diagnostics</p></td> <td><p>Quotient ADHD system is designed to objectively measure brain functions and help diagnose attention-deficit hyperactivity disorder</p></td> <td><p>Undisclosed</p></td> <td><p>$5.2m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Biomimedica</b></p></td> <td><p>Orthopaedics</p></td> <td><p>GRADION total cartilage replacement technology is synthetic cartilage for joint repairs</p></td> <td><p>Troika Ventures, Biedermann Motech, Emergent Medical Partners  and Asset Management Ventures</p></td> <td><p>$11.9m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>CD Diagnostics</b></p></td> <td><p>IVD</p></td> <td><p>Joint fluid assays</p></td> <td><p>Undisclosed</p></td> <td><p>$5m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>CellScope</b></p></td> <td><p>Healthcare IT/ Diagnostics</p></td> <td><p>Smartphone peripheral devices that enable the user to turn their smartphones into diagnostic tools. The first -enabled otoscope to diagnose ear infections in children</p></td> <td><p>Khosla Ventures </p></td> <td><p>$1m</p></td> <td><p>Seed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Cohera Medical</b></p></td> <td><p>Surgery</p></td> <td><p>Absorbable surgical adhesives and sealants. Cohera's first product is TissueGlu surgical adhesive; the company is also developing the FlexSil surgical sealant for bowel repair</p></td> <td><p>Private investors</p></td> <td><p>$8.4m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>EndoGastric Solutions</b></p></td> <td><p>Surgery</p></td> <td><p>EsophyX is a device used in combination with transoral incisionless fundoplication to restore gastroesophageal valve and restore its ability to block acid reflux</p></td> <td><p>Advanced Technology Ventures, Canaan Partners, Chicago Growth Partners, De Novo Ventures, Foundation Medical, Oakwood Medical Investors and Radius Ventures</p></td> <td><p>$13m</p></td> <td><p>Series F2</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Grove Instruments</b></p></td> <td><p>Patient monitoring</p></td> <td><p>Blood glucose monitoring</p></td> <td><p>Private investors</p></td> <td><p>$2.5m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>HyperBranch Medical Technology</b></p></td> <td><p>Surgery</p></td> <td><p>Polymer-based surgical sealants for use in range of applications including ophthalmic, dural, hernia repair, spinal and cardiovascular</p></td> <td><p>Undisclosed</p></td> <td><p>$1.7m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Invuity</b></p></td> <td><p>Surgery</p></td> <td><p>The company incorproates its proprietary Eigr illumination technology into advanced access systems used in various minimally invasive surgical procedures </p></td> <td><p>Valence Advantage Life Sciences Fund II, Kleiner Perkins Caufield &amp; Byres and InterWest Partners</p></td> <td><p>$25m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>JustRight Surgical</b></p></td> <td><p>Surgery</p></td> <td><p>Low-power tissue sealing device</p></td> <td><p>Undisclosed</p></td> <td><p>$6.6m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>NeuroSave</b></p></td> <td><p>Neurovascular</p></td> <td><p>Therapeutic hypothermia system for treating patients after cardiac arrest or traumatic brain surgery</p></td> <td><p>Undisclosed</p></td> <td><p>$1.5m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>NexDx</b></p></td> <td><p>IVD</p></td> <td><p>Molecular diagnostic tests for personalised medicine in rheumatoid arthritis and other autoimmune diseases</p></td> <td><p>City Hill Ventures</p></td> <td><p>$2.1m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>NovaTract Surgical</b></p></td> <td><p>Surgery</p></td> <td><p>Laparoscopic devices for minimally invasive surgery. NovaTract's first product is an organ retraction device that allows surgeons to carry out more easily single-incision and natural orific transluminal endoscopic surgery devices</p></td> <td><p>Undisclosed</p></td> <td><p>$3.2m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Oxford Immunotec</b></p></td> <td><p>IVD</p></td> <td><p>T-SPOT TB is an interferon-gamma release assay which detects latent TB infection. It is the first test from Oxford Immunotec's T-SPOT platform for directly quantifying antigen-specific T cells</p></td> <td><p>Imperial Innovations, Invesco Perpetual, Clarus, New Leaf, DFJ Esprit, Wellington, SPARK Ventures, Dow Chemical Company, NTEC, Kaiser Permanente Ventures and the University of Oxford</p></td> <td><p>$28m</p></td> <td><p>Series E</p></td> <td><p>$110m</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>ProTip </b></p></td> <td><p>ENT</p></td> <td><p>ENTegral is a permanent implant to replace the larynx in patients who have undergone total laryngectomy</p></td> <td><p>Seventure, Fonds Lorrain des Materiaux, the Berchet family-office, Alsace Amorcage and other private investors</p></td> <td><p>$4.7m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>SentreHEART </b></p></td> <td><p>Surgery</p></td> <td><p>The Lariat suture delivery device is designed for the remote delivery of a pre-tied suture loop for closing soft tissue wounds in catheter-based procedures</p></td> <td><p>VivoVentures, US Venture Partners and Prospect Ventures</p></td> <td><p>$26m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Seventh Sense Biosystems</b></p></td> <td><p>Blood collection/IVD</p></td> <td><p>Touch Activated Phlebotomy is a painless blood sampling platform. The initial application is for use in the field of in vitro diagnostic testing </p></td> <td><p>Flagship Ventures, Polaris Venture Partners</p></td> <td><p>$10m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>SurgaColl Technologies</b></p></td> <td><p>Orthopaedics</p></td> <td><p>Tissue regeneration products. SurgaColl's first product is HydroxyColl, a bone graft substitute </p></td> <td><p>AIB Seed Capital Fund, Harmac Medical Products, Enterprise Ireland and private investors</p></td> <td><p>&euro;2m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Svelte Medical Systems</b></p></td> <td><p>Cardiovascular</p></td> <td><p>Acrobat is a drug-eluting coronary stent</p></td> <td><p>Apjohn Ventures Fund, CNF Investments, Norwich Ventures and company founders</p></td> <td><p>$8m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>EyeNetra</b></p></td> <td><p>Ophthalmology</p></td> <td><p>EyeNetra is developing a suite of cloud-based mobile eye diagnostic tests. </p></td> <td><p>Undisclosed</p></td> <td><p>$1m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Neuros Medical</b></p></td> <td><p>Neurology</p></td> <td><p>Neuros has initiated pilot trials in the US on it high-frequency Electrical Nerve Block technology for use in acute treatment of pain in the residual limb of amputees.</p></td> <td><p>Boston Scientific, Glengary, Case Tech Ventures, JumpStart Ventures, NorthCoast Angel Fund, Ohio Tech Angel Fund, Queen City Angel Fund III, Physician Investment Group RiverVest Venture Partners Blue Tree Allied Angels ModelVest </p></td> <td><p>$3.5m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Obalon Therapeutics</b></p></td> <td><p>Bariatric surgery</p></td> <td><p>Obalon has initiated a US clinical trial of its gastric balloon system. The device consists of a capsule containing a balloon that is swallowed and then remotely inflated. The balloon occupies space in the stomach to promote an artificial sense of fullness.</p></td> <td><p>InterWest Partners, Domain Associates, Okapi Venture Capital</p></td> <td><p>$16.5m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Valcare Medical</b></p></td> <td><p>Cardio/Peripheral vascular</p></td> <td><p>Valcare, a spinoff of MiCardia, is developing a transatheter mitral valve repair system</p></td> <td><p>Accelmed</p></td> <td><p>$8m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Avinger</b></p></td> <td><p>Cardiovascular imaging</p></td> <td><p>Avinger has just completed its CONNECT II global clinical trial of Ocelot, a crossing catheter with integrated real-time intravascular imaging, used for treating peripheral artery disease. The firm is also developing Wolverine, a peripheral atherectomy catheter with integrated intravascular imaging technology using optical coherence tomography.</p></td> <td><p>Undisclosed</p></td> <td><p>$33m</p></td> <td><p>Series D</p></td> <td><p>Around $80m</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>CartiHeal</b></p></td> <td><p>Regenerative medicine</p></td> <td><p>CartiHeal is developing implants for regeneration of cartilage and bone disorder. The firm's lead product is Agili-C is an arthroscopically-place implant used for repairing cartilage and osteochondral defects.</p></td> <td><p>Elron, Accelmed, Access Medical Ventures</p></td> <td><p>$10m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Lantos Technologies</b></p></td> <td><p>ENT</p></td> <td><p>Lantos has developed a 3D intra-aural digital scanner for dynamic imaging the ear canal. This helps to improve the fitting of hearing aids and other audio devices.</p></td> <td><p>Undisclosed</p></td> <td><p>$3.8m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Harmonic Cold Plasma</b></p></td> <td><p>Woundcare</p></td> <td><p>Harmomic's Wound Care Systems 1000  is developing a portable hand held device that converts a noble gas mixutre into a cold plasma state and delivers it to the site of a wound. This helps to eradicate potentially infectious bacteria, fungi and viruses, and can also accelerate the body's natural healing process at the cellular level.  </p></td> <td><p>Undisclosed</p></td> <td><p>$1m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Beacon Endoscopic</b></p></td> <td><p>Endoscopy/ Surgery</p></td> <td><p>Beacon's BNX system is a fine needle aspiration platform for use in endoscopic ultrasound and endoscopic bronchial ultrasound. </p></td> <td><p>Undisclosed</p></td> <td><p>$1.25m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>iWalk</b></p></td> <td><p>Bionic prosthetics</p></td> <td><p>iWalk develops bionic prosthetics to restore natural movement for lower-limb amputees. </p></td> <td><p>(from previous round) Sigma Partners, General Catalyst Partners, WFD Ventures</p></td> <td><p>$3.1m (debt financing)</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Clinithink</b></p></td> <td><p>Healthcare IT</p></td> <td><p>Clinithink's CLiX technology is a clinical language indexing software that structures the free text in electronic medical records.</p></td> <td><p>Vanguard Atlantic</p></td> <td><p>Undisclosed</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Cardiosolutions</b></p></td> <td><p>Cardio/peripheral vascular</p></td> <td><p>Cardiosolutions' lead product is a transcatheter-placed implantable device, the Mitra-Spacer, designed to treat moderate to severe mitral valve regurgitation </p></td> <td><p>Sorin</p></td> <td><p>$8m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Neuravi</b></p></td> <td><p>Cardio/Peripheral vascular</p></td> <td><p>Neuravi is developing a mechinical clot retrieval device, based on its Stent Basket technology, which will be used on acute ischaemic stroke patients. </p></td> <td><p>Fountain Healthcare Partners, Delta Partners</p></td> <td><p>&euro;5.2m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>IntegraGen</b></p></td> <td><p>IVD</p></td> <td><p>IntegraGen is developing molecular diagnostics for autism.</p></td> <td><p>A Plus Finance</p></td> <td><p>&euro;2m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Histogenics</b></p></td> <td><p>Regenerative medicine</p></td> <td><p>Histogenics is conducting Phase 3 trials of its NeoCart autologous neocartilage tissue implant.</p></td> <td><p>Sofinnova Ventures, Split Rock Partners, BioMed Ventures, FinTech GIMV Fund</p></td> <td><p>$49m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Allurion Technologies</b></p></td> <td><p>Bariatric surgery</p></td> <td><p>Allurion is developing a balloon device that is delivered in a pill which the patient swallows. The balloon expands in the stomach over several months and helps the patient feel full while consuming less food. </p></td> <td><p>Undisclosed</p></td> <td><p>$1.7m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Zonare Medical Systems</b></p></td> <td><p>Imaging</p></td> <td><p>Zonare commercialises diagnostic ultrasound devices, based on its zone sonography technology, used in different clinical applications</p></td> <td><p>Oxford Finance for current debt financing. Equity investors include Apposite Capital, Ascension Health, CB Health Ventures, Frazier Healthcare Ventures, Greenspring Associates, Mosaix Ventures, ePlanet Ventures, Texas Instruments, Earlybird</p></td> <td><p>$25 debt financing</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Intuity Medical</b></p></td> <td><p>Diabetes management</p></td> <td><p>The Pogo complete blood glucose monitoring system eliminates the need for separate testing supplies</p></td> <td><p>Undisclosed</p></td> <td><p>$12m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Retia Medical</b></p></td> <td><p>Patient monitoring</p></td> <td><p>Retia is developing a new, less-invasive system to monitor cardiac output (CO) and other key measures of the cardiovascular system accurately when patients go into shock.</p></td> <td><p>Pritzker/Vlock family office</p></td> <td><p>$7m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Medrobotics</b></p></td> <td><p>Surgery</p></td> <td><p>Medrobotics' robotic surgical products include the cardioARM, a robotic probe controlled remotely and designed to enable surgeries with minimal or no incisions. </p></td> <td><p>Eagle Ventures, The Pittsburgh Life Sciences Greenhourse and other investors</p></td> <td><p>$8m</p></td> <td><p>Series D</p></td> <td><p>$36.3m</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>EpiEP</b></p></td> <td><p>Surgery</p></td> <td><p>EpiEP has developed a system that provides cardiac surgeons with minimally invasive access to the epicardium, the outer layer heart tissue</p></td> <td><p>Conneticut Innovation, LaunchCapital and private investors</p></td> <td><p>$2.75m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Nuclea Biotechnologies</b></p></td> <td><p>IVD</p></td> <td><p>Nuclea is developing a suite of companion diagnostic assays  for use in therapeutic and medical imaging applications across the five major cancer types: colon, stomach, leukemia, lung and prostate. </p></td> <td><p>Undisclosed</p></td> <td><p>$5m</p></td> <td><p>Series C</p></td> <td><p>$35.9m</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Ikonisys</b></p></td> <td><p>IVD</p></td> <td><p>Ikonisys' portfolio of cell-based diagnostics incorporating its CellOptics platform for rare cell detection.</p></td> <td><p>Undisclosed</p></td> <td><p>$1.4m (converted debt to equity)</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Vayyar Imaging</b></p></td> <td><p>Imaging</p></td> <td><p>Vayyar is developing a processor that uses radiofrequency waves to image and detect breast cancer at an early stage.</p></td> <td><p>Battery Ventures, Bessemer Venture Partners, Israel Cleantech Ventures</p></td> <td><p>$12m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Ornim</b></p></td> <td><p>Patient monitoring</p></td> <td><p>Ornim's CE-marked and FDA-cleared CerOx noninvasively monitors blood flow and oxygen saturation in brain and muscle tissue. </p></td> <td><p>GE, OrbiMed Israel Partners, Agate-MAC Fund</p></td> <td><p>$20m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Sapheon</b></p></td> <td><p>Cardio/ Peripheral vascular</p></td> <td><p>The VenaSeal closure system is designed to treat venous reflux disease</p></td> <td><p>Undisclosed</p></td> <td><p>$8.6m</p></td> <td><p>First tranche of Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>CardioDx</b></p></td> <td><p>IVD</p></td> <td><p>CardioDx's Corus CAD is a gene expression test to identify symptomatic patients unlikely to develop obstructive coronary artery disease</p></td> <td><p>Temasek, Kleiner Perkins Caufield &amp; Byers, Mohr Davidow Ventures, TPG Biotech, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Group, GE Capital, Longitude Capital, JP Morgan, Acadia Woods Partners, Artiman Ventures, Bright Capital </p></td> <td><p>$58m</p></td> <td><p>Series F</p></td> <td><p>Over $175m</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Acutus Medical</b></p></td> <td><p>Cardiology</p></td> <td><p>Acutus is developing an electrophysiology diagnostics system to map cardiac arrhythmias</p></td> <td><p>Advent Life Sciences, Index Ventures, private investors</p></td> <td><p>$2.5m</p></td> <td><p>Expanded Series A</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Biodesix</b></p></td> <td><p>IVD</p></td> <td><p>Biodesix's first product is VeriStrat, a blood-based test to help personalise drug treatment for patients with non-small cell lung cancer</p></td> <td><p>Undisclosed</p></td> <td><p>$12m</p></td> <td><p>Expanded series D</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>VitaPath Genetics</b></p></td> <td><p>IVD</p></td> <td><p>VitaPath is focused on commercialising assays that test vitamin-remediable genetic variants. Its first test is a folate metabolism test to help assess a woman's preconception risk of having a spina bifida-affected pregnancy. </p></td> <td><p>Undisclosed</p></td> <td><p>$5m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>OmniGuide</b></p></td> <td><p>Surgery</p></td> <td><p>OmniGuide's BeamPath flexible CO2 laser system for minimally invasive surgery is used in gynaecology, ENT and neurosurgery. </p></td> <td><p>Stata Ventures, Psilos Group, ESI, Argonaut Ventures, Alliance Technology Ventures, Apposite Capital, Friday Street Ventures, Westbury Partners and OrbiMed Advisors </p></td> <td><p>$35m (non-dilutive growth financing from Orbimed only)</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Mainstay Medical</b></p></td> <td><p>Orthopaedics</p></td> <td><p>Mainstay is developing a device for treating patients with chronic non-specific low  back pain.</p></td> <td><p>Fountain Healthcare Partners, Medtronic, Capricorn Venture Partners, Seventure Partners, Sofinnova Partners and Twin City Angels</p></td> <td><p>$20m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>IlluminOss Medical</b></p></td> <td><p>Orthopaedics</p></td> <td><p>IlluminOss's CE marked photodynamic bone stabilisation system is used to treat fractures in low load bearing bones. It incorporates a proprietary bone-filling liquid monomer that polymerises into a solid on exposure to a visible light source. </p></td> <td><p>Tekla Capital Management, Life Sciences Partners, Foundation Medical Partners, Mieza Capital, New Leaf Venture Partners, SR One, Excel Venture Management, Pappas Ventures, Slater Technology Fund</p></td> <td><p>$28m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Foundation Medicine</b></p></td> <td><p>IVD</p></td> <td><p>FoundationOne is a genomic assay for all solid tumours that identifies oncogenic alterations in the tumour to help tailor drug therapy for patients</p></td> <td><p>Deerfield Management Company, Casdin Capital, Redmile Group, Roche Venture Fund, WuXi Corporate Venture Fund, Kleiner Perkins Caufield &amp; Byers</p></td> <td><p>$42.5m </p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>ABT Molecular Imaging</b></p></td> <td><p>Diagnostic imaging</p></td> <td><p>ABT markets a generator which produces, at point of use, unit doses of molecular imaging drugs for positron emission tomography </p></td> <td><p>River Cities Capital Funds, Mountain Group Capital, Council Capital, Intersouth Partners</p></td> <td><p>$6m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>iWalk</b></p></td> <td><p>Orthopaedics</p></td> <td><p>iWalk manufactures personalised bionic foot and ankle systems</p></td> <td><p>Gilde Healthcare Partners, WFD Ventures, General Catalyst Partners, Sigma Partners </p></td> <td><p>$17m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Torax Medical</b></p></td> <td><p>Surgery</p></td> <td><p>Torax's FDA-approved LINX reflux management system is a surgical treatment for gastroesophageal reflux disease (GERD)</p></td> <td><p>Piper Jaffray Merchant Banking, Sanderling Ventures, Thomas McNerney &amp; Partners, Accuitive Medical Ventures, Kaiser Permanente, Mayo Medical Ventures</p></td> <td><p>$30m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>BioFire Diagnostics</b></p></td> <td><p>IVD</p></td> <td><p>BioFire develops rapid multiplex tests based on  its FilmArray diagnostic platform. It markest its respiratory panel, FilmArray, in the US and Europe and is developing other tests including blood culture identification, gastrointestinal and meningitis panels.</p></td> <td><p>Undisclosed</p></td> <td><p>$25m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Intact Vascular</b></p></td> <td><p>Cardio/ Peripheral vascular</p></td> <td><p>The Tack-It endovascular stapler device is desiged to optimise peripheral angioplasty results for treatment of peripheral artery disease. It is currently being trialled in Europe and expected to be CE marked end of 2012</p></td> <td><p>Quaker Partners, HIG BioVentures, angel investors</p></td> <td><p>$15.5m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>NeuWave Medical</b></p></td> <td><p>Surgery</p></td> <td><p>The Certus 140 microwave ablation system is FDA-cleared for the coagulation of soft tissue</p></td> <td><p>HIG BioVentures, Venture Investors, WARF, State of Wisconsin Investment Board</p></td> <td><p>$14m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Apnex Medical</b></p></td> <td><p>Neurology</p></td> <td><p>Apnex's implantable Hypoglossal Nerve Stimulation System electrically stimulates the muscles that control breathing to treat patients with obstructive sleep apnoea. The device is underoing clinical trials.</p></td> <td><p>New Enterprise Associates, Domain Associates, Polaris Venture Partners, Michael Berman</p></td> <td><p>$10m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Exagen Diagnostics</b></p></td> <td><p>IVD</p></td> <td><p>Exagen specialises in tests for rheumatologic disorders. It commercialises Avise SLE for testing systemic lupus erythematosus, Avise PG to measure how well the body metabolises methotrexate (a treatment for rheumatoid arthritis) and Avise MCV, for diagnosing rheumatoid arthritis.</p></td> <td><p>Tullis Health Investors, Sun Mountain Capital, Cottonwood Technology Fund, Mesa Verde Venture Partners, Epic Ventures</p></td> <td><p>$5.3m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Tandem Diabetes Care</b></p></td> <td><p>Diabetes management</p></td> <td><p>Tandem's FDA-cleared t:slim insulin delivery system is a pocket-sized full-featured insulin pump with a colour touch screen.  </p></td> <td><p>Undisclosed</p></td> <td><p>$36.4m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Provista Diagnostics</b></p></td> <td><p>IVD</p></td> <td><p>Provista is completing confirmatory clinical trials for its dtectDx-Breast blood test. The product is used in conjunction with mammography to help early detection of breast cancer. </p></td> <td><p>Undisclosed</p></td> <td><p>$2.5m</p></td> <td><p>Second tranche of Series A</p></td> <td><p>$7.5m</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Aushon BioSystems</b></p></td> <td><p>IVD</p></td> <td><p>The Cira immunoassay platform is designed to perform multiplex analysis with the affordability, sensitivity and consistency of singleplex ELISA, but 25 times faster and using 23 times less material.</p></td> <td><p>Undisclosed</p></td> <td><p>$5.5m</p></td> <td><p>Undisclosed</p></td> <td><p>$24m</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Bio2 Medical </b></p></td> <td><p>Cardio/ peripheral vascular</p></td> <td><p>The Angel catheter, named after its inventor and Bio2's chief medical officer Dr Luis Angel, is a central venous catheter and inferior vena cava filter combination device for protection against pulmonary embolism.</p></td> <td><p>Incyte Ventures Targeted Technology Fund, Remeditex Ventures</p></td> <td><p>$12m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Verax Biomedical</b></p></td> <td><p>IVD</p></td> <td><p>Verax's Platelet PGD Test is a rapid diagnostic for detecting bacterial contamination in blood platelets hours before transfusion. The FDA-cleared test is based on the company's Pan Genera Detection technology. </p></td> <td><p>Undisclosed</p></td> <td><p>$3.3m </p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Biom'Up</b></p></td> <td><p>Regenerative medicine/ Surgery</p></td> <td><p>Biom'Up is already commercialising 1)COVA, a membrane used in surgery to prevent adhesions and controlled healing, in the EU and US and 2)MATRI BONE, a bone regeneration matrix, in the EU</p></td> <td><p>CDC Enterprises/InnoBio, Viveris Management, OTC Asset Management, Merieux Developpement, SHAM, Sofimac Partners, Aquasourca, L'Ameliane and Biom'Up's founders</p></td> <td><p>&euro;6.8m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Quantason</b></p></td> <td><p>Imaging</p></td> <td><p>Quantason is completing the development of its Idus biomodal ultrasound technology, designed for visualising breast premalignant lesions, such as clusters and grouped microcalcifications. </p></td> <td><p>Private investors</p></td> <td><p>$3.2m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Spinal Restoration</b></p></td> <td><p>Regenerative medicine </p></td> <td><p>The Biostat System is an intradiscal biologic therapy for discogenic low back pain. It consists of the Biologx fibrin sealant, a human-derived resorbable biologic tissue sealant which is delivered to the intervertebral disc via the Biostat delivery device.</p></td> <td><p>Austin Ventures Sante Ventures and MB Ventures </p></td> <td><p>$3m (plus $2m debt financing from Comerica Bank)</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Nanostim</b></p></td> <td><p>Cardiology</p></td> <td><p>Nanostim is developed miniaturised, leadless pacemakers.</p></td> <td><p>St Jude Medical, InterWest Partners, US Venture Partners, Emergent Medical Partners, Life Sciences Angels and other private investors</p></td> <td><p>$10m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Cibiem</b></p></td> <td><p>Neurology</p></td> <td><p>Cibiem using a proprietary Carotid Body Modulation (CBM) approach to treat sympathetic nervous system-mediated diseases such as hypertention, heart failure, diabetes and renal failure. The firm is already in first-in-man clinical trials.</p></td> <td><p>SV Life Sciences, Third Rock Ventures</p></td> <td><p>$10m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Lanx</b></p></td> <td><p>Orthopaedics</p></td> <td><p>Lanx is focused on minimally invasive spinal surgical products and is commercialising a wide range of devices and fusion systems.</p></td> <td><p>Undisclosed</p></td> <td><p>$8.7m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>BiOxyDyn</b></p></td> <td><p>Imaging</p></td> <td><p>BiOxyDyn is developing diagnostic imaging solutions for lung disease, with particular application in chronic obstructive pulmonary disorder and asthma. The company also provides quantitative medical imaging services to the pharmaceutical industry.</p></td> <td><p>The North West Fund for Biomedical, UMIP Premier Fund</p></td> <td><p>&pound;1.2m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Definiens</b></p></td> <td><p>Digital pathology</p></td> <td><p>Definiens has developed the Cognition Network Technology used for image analysis in digital pathology. The technology is used for R&amp;D purposes by pharma companies and an increasing number of diagnostic companies in tissue-based diagnostic biomarker development.</p></td> <td><p>Gilde Healthcare Partners, TVM, Cipio and Definiens' management</p></td> <td><p>&euro;10m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>LoneStar Heart</b></p></td> <td><p>Regenerative medicine/ Cardiology</p></td> <td><p>LoneStar has developed the Algisyl0LVR, a biopolymer that is injected into the heart's left ventricle during surgery and remain in the heart muscle as permanent implants to support the injured heart, reducing the ventricle's tension and stress</p></td> <td><p>Themes Investment Partners and others</p></td> <td><p>Up to $20m (includes milestones)</p></td> <td><p>Undisclosed </p></td> <td><p>Up to $35m</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>EyeBrain</b></p></td> <td><p>Neurology</p></td> <td><p>EyeBrain is developing brain function markers for neurological and psychiatric diseases using its Mobile EyeBrain Tracker that records and analyses eye movements.</p></td> <td><p>Octalfa, Sudinnova, CM-CIC Capital Innovation, CapDecisif Management, G1JIDF</p></td> <td><p>&euro;3.3m</p></td> <td><p>Series B</p></td> <td><p>&euro;4.5m</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>BioBehavioral Diagnostics</b></p></td> <td><p>Neurology</p></td> <td><p>BioBehavioral has developed the Quotient ADHD test system. The device measures a person's ability to think by assessing motion and attention state, thereby providing data on hyperacitivity, impulsivity and inattention.</p></td> <td><p>Undisclosed</p></td> <td><p>$2.5m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>GnuBIO</b></p></td> <td><p>IVD</p></td> <td><p>GnuBIO will be commercialising in 2013 its desktop system for performing targeted and whole genmoe sequencing. The entire process is all on the chip and the results ready in hours. </p></td> <td><p>Private investors</p></td> <td><p>$10m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Tactile Systems Technology</b></p></td> <td><p>Chronic disease management</p></td> <td><p>Tactile's Flexitouch system is designed for at-home treatment of lymphedema, chronic ediema and non-healing venous ulcers</p></td> <td><p>Galen Partners and private investors</p></td> <td><p>$10.4m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>OptiScan Biomedical</b></p></td> <td><p>Patient monitoring</p></td> <td><p>The OptiScanner is a continuous glucose monitoring system designed for use in the intensive care unit.</p></td> <td><p>Undisclosed</p></td> <td><p>$5.1m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Trivitron Healthcare</b></p></td> <td><p>Medical devices distribution</p></td> <td><p>Trivitron is India's largest wholesale distributor and after-sales support provider of medical equipment and devices. It specialises in imaging, lab diagnostics, cardiology, critical care, renal care, operating room and ophrhalmology equipment. </p></td> <td><p>Fidelity Growth Partners India</p></td> <td><p>INR400 crores ($75m) </p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>CardiAQ Valve Technologies</b></p></td> <td><p>Cardiology</p></td> <td><p>CardiAQ is developing a proprietary system for transcatheter mitral valve implantation. </p></td> <td><p>Orbimed, Versant Ventures, Advent Life Sciences and private investors</p></td> <td><p>$37.3m</p></td> <td><p>Series B</p></td> <td><p>$43.8m</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>Endosense</b></p></td> <td><p>Cardiology</p></td> <td><p>Endosense has CE-marked and is commercialising its TactiCath force-sensing catheter ablation technology, used to treat cardiac arrhythmias. It is completing US trials of its technology to gain FDA approval.</p></td> <td><p>NGN Capital, Edmond de Rothschild Investment Partners, NeoMed Management, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie and private investors</p></td> <td><p>$40.3m</p></td> <td><p>Series C</p></td> <td><p>$96.3m</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>GlySure</b></p></td> <td><p>Patient monitoring</p></td> <td><p>Glysure has developed a continuous blood glucose monitoring ystems for use in the intensive care unit in hospitals. </p></td> <td><p>Amadeus Capital Partners, Chester Investments, Delta Partners, Morningside Ventures and private investors</p></td> <td><p>$13.6m</p></td> <td><p>Series C-2</p></td> <td><p>$22.4m</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>EarlySense</b></p></td> <td><p>Patient monitoring</p></td> <td><p>EarlySense has developed a non-contact system that continuously monitors a patient's vital signs and movement using a sensor that is placed underneath a bed mattress. There are no leads , cuffs or attachements connected to the patient, who is allowed complete freedom of movement.</p></td> <td><p>Pitango Venture Capital, JK&amp;B, ProSeed VC Fund, Docor International Management, Bridge Investment Fund</p></td> <td><p>$15m</p></td> <td><p>Series E</p></td> <td><p>Undisclosed</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>Epic Sciences</b></p></td> <td><p>IVD</p></td> <td><p>Epic is developing diagnostic tests that can detect and profile biomarkers on circulating tumour cells in the blood, to provide a noninvasive method of detecting cancer and monitoring and personalising cancer drug treatments.</p></td> <td><p>Domain Associates, Roche Venture Fund, Pfizer Venture Investments and private investors</p></td> <td><p>$13m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>Quanterix</b></p></td> <td><p>IVD</p></td> <td><p>Quanterix's Simoa multiplex immunoassay technology is based on a digital approach that enables detection of a signal from single molecules of a labelled analyte, and is much more sensitive than conventional analog-based protein detection technologies.</p></td> <td><p>bioMerieux, ARCH Venture Partners, Bain Capital Ventures, Flagship Ventures and In-Q-Tel</p></td> <td><p>$18.5m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>Metamark Genetics</b></p></td> <td><p>IVD</p></td> <td><p>MetaMark is developing two prostate cancer prognostic tests. The first is a tissue-based test to determine whether the cancer is a slow-growing or aggressive form, and the second predicts the longer-term course of disease.</p></td> <td><p>Private investors</p></td> <td><p>$13m</p></td> <td><p>Series B</p></td> <td><p>Around $43m</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>Seno Medical Instruments </b></p></td> <td><p>Imaging</p></td> <td><p>Seno has developed an opto-acoustic imaging technology for detecting breast cancer.</p></td> <td><p>Undisclosed</p></td> <td><p>$14.5m of a larger $21m round</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>TriReme Medical</b></p></td> <td><p>Cardio-/ Peripheral Vascular</p></td> <td><p>TriReme specialises in balloon catheters for treating complex coronary and peripheral vascular disease.</p></td> <td><p>Luminor Capital, Bio*One Capital, Three Arch Partners and Adams Street Partners</p></td> <td><p>$18m</p></td> <td><p>Series E</p></td> <td><p>Undisclosed</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>Tangent Medical Technologies</b></p></td> <td><p>Vascular access</p></td> <td><p>Tangent has developed NovaCath, an FDA-cleared closed-system IV device. </p></td> <td><p>Undisclosed</p></td> <td><p>$8.6m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>NICO</b></p></td> <td><p>Surgery</p></td> <td><p>Myriad, NICO's lead device, is an automated non-heat-generating surgical tool for removing damaged tissue from the brain and spine.</p></td> <td><p>Rose-Hulman Institute of Technology, River Cities Capital Fund, CHV Capital, Cornelius Private Investments and Twilight Venture Partners</p></td> <td><p>$6.5m</p></td> <td><p>Undisclosed </p></td> <td><p>Over $20m</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>iRhythm Technologies</b></p></td> <td><p>Cardiology</p></td> <td><p>iRhythm's Zio Patch is a single-use, water-resistant continuous cardiac rhythm monitoring device that can be worn for up to 14 days. It is used for early diagnosis of cardiac arrhythmia.</p></td> <td><p>Undisclosed</p></td> <td><p>$3.5m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>OptiMedica</b></p></td> <td><p>Ophthalmology</p></td> <td><p>OptiMedica is commercialising its FDA-cleared and CE-marked Catalys Precision Laser System for performing cataract surgery.</p></td> <td><p>Kleiner Perkins Caufield &amp; Byers, Alloy Ventures, DAG Ventures, BlackRock Private Equity Partners and Bio*One Capital </p></td> <td><p>$35m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>Advanced Cell Diagnostics</b></p></td> <td><p>IVD</p></td> <td><p>ACD develops cell- and tissue-based diagnostic tests for personalised medicine, based on its proprietary RNAscope technology.</p></td> <td><p>New Leaf Venture Partners, Morningside Ventures</p></td> <td><p>$12m</p></td> <td><p>Series B</p></td> <td><p>$17.4m</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>Ignyta</b></p></td> <td><p>IVD</p></td> <td><p>Ignyta is initiating in 2013 clinical trials of its Enlyta molecular assays  for diagnosing rheumatoid arthritis at its earliest, most treatable stages</p></td> <td><p>Colt Ventures, City Hill Ventures, private investors</p></td> <td><p>$3.4m</p></td> <td><p>Series B-2</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Magenta Medical</b></p></td> <td><p>Cardiology</p></td> <td><p>Magenta is an early-stage start-up developing medical device for treating acute and chornic heart failure.</p></td> <td><p>Pitango Venture Capital</p></td> <td><p>$4m</p></td> <td><p>Seed</p></td> <td><p>n/a</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Cardiosonic </b></p></td> <td><p>Neurology</p></td> <td><p>Cardiosonic's TIVUS catheter-based system uses high-intensity, non-focused ultrasound energy to perform remote renal denervation to treat hypertension, without damaging the arterial endothelium. </p></td> <td><p>Private investors</p></td> <td><p>$6.1m</p></td> <td><p>Series B-1</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Kona Medical</b></p></td> <td><p>Neurology</p></td> <td><p>Kona is conducting clinical trials of Surround Sound, its fully noninvasive system that delivers ultraound outside the body to ablate renal nerves to treat hypertension.</p></td> <td><p>Unnamed large-cap strategic investors, Essex Woodlands, Domain Associates, Morgenthaler Ventures, Western Technology Investments, BioStar Ventures</p></td> <td><p>$40m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Nanostring Technologies</b></p></td> <td><p>IVD</p></td> <td><p>Nanostring provides a gene profiling service, using its nCounter analysis system, for life sciences research applications; it has also developed its first molecular diagnostic product, a breast cancer assay based on the PAM50 gene expression signature.</p></td> <td><p>Morgan Stanley Expansion Capital, Alliance Bernstein Alternative Investment Management Group, Clarus Ventures, Draper Fisher Jurvetson, OVP Venture Partners, GE healthymagination Fund, BioMed Ventures, Henri Termeer</p></td> <td><p>$15.3m</p></td> <td><p>Series E</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Avelas Biosciences</b></p></td> <td><p>Imaging</p></td> <td><p>The Avelas Cancer Illuminator (ACI) allows real-time visualisation of metastatic nodes to allow surgeons to remove additional nodes during the first surgery, and eliminate the need for the patient to undergo a subsequent surgical procedure. </p></td> <td><p>Avalon Ventures</p></td> <td><p>$7.65m</p></td> <td><p>Series A</p></td> <td><p>n/a</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Innovative Trauma Care (ITC)</b></p></td> <td><p>Wound management</p></td> <td><p>The ITClamp haemorrhage control system is designed to control rapidly critical bleeding. It is approved for sale in Canada, and ITC expects to CE mark and gain FDA clearance in 2013.</p></td> <td><p>Undisclosed</p></td> <td><p>$3.6m</p></td> <td><p>Series A</p></td> <td><p>n/a</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Biocartis</b></p></td> <td><p>IVD</p></td> <td><p>BioCartis's Apollo rapid and fully-automated molecular diagnostics platform was acquired from Philips in 2010. The company is now developing a medu of oncology tests to run on the system.</p></td> <td><p>PMV, RMM Valiance, Debiopharm Group, Korys, Philips, J&amp;J Development Corp, family office of Dr Paul Janssen, Luc Verelst, Benaruca, New Rhein Healthcare</p></td> <td><p>&euro;34.5m</p></td> <td><p>Series D</p></td> <td><p>&euro;145.5m</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Angel Medical Systems</b></p></td> <td><p>Cardiology</p></td> <td><p>The CE-marked AngelMed Guardian system is an implantable cardiac device designed to continuously monitor the patient's heart signals, detect changes that may indicate the onset of a heart attack and alert the patient to seek medical attention.</p></td> <td><p>SOAM Angel Partners and other VC, strategic and angel investors</p></td> <td><p>$27.5m </p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Sharklet Technologies</b></p></td> <td><p>Surface technology</p></td> <td><p>Sharklet has developed a bacteria-inhibiting microtexture surface technology that can be incorporated into medical devices  - such as endotracheal tube and central venous catheter - that potentially act as a conduit for bacteria to enter the body. </p></td> <td><p>Altria Ventures</p></td> <td><p>$2m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Cerapedics </b></p></td> <td><p>Regenerative medicine/ Orthopaedics </p></td> <td><p>Cerapedics' CE-marked i-FACTOR bone graft is said to be the only biologic bone graft that uses a synthetic small peptide as an attachment factor to stimulate the natural bone healing process, at a fraction of the cost of biologic growth factors.</p></td> <td><p>MedImmune Ventures, CVF, OrbiMed Advisors, NGN Capital</p></td> <td><p>$19m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>DioGenix</b></p></td> <td><p>IVD</p></td> <td><p>DioGenix is clinically validating MSPreciseits next-generation gene sequencing test for the early identification and diagnosis of multiple sclerosis </p></td> <td><p>Nervada</p></td> <td><p>$1.5m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Ortho Kinematics</b></p></td> <td><p>Orthopaedics</p></td> <td><p>Ortho Kinematics specialises in spine imaging informatics, Its proprietary VMA (vertebral motion analysis) technology provides spine biomechanical data to help improve the diagnosis and treatment of back pain. </p></td> <td><p>Texo Ventures, PTV Sciences, Gatebridge Investments, Texas Emerging Technology Fund </p></td> <td><p>$2m</p></td> <td><p>Series B</p></td> <td><p>$7.5m</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Medrobotics</b></p></td> <td><p>Surgery</p></td> <td><p>Medrobotics' Flex robotic system enables surgeons to gain single-site access and visualisation to difficult-to-access anatomical structures.</p></td> <td><p>Undisclosed</p></td> <td><p>$33.6m</p></td> <td><p>Series D</p></td> <td><p>$62m</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>SurgiQuest</b></p></td> <td><p>Surgery</p></td> <td><p>SurgiQuest develops devices for use in laparascopic procedures. Its portfolio includes  AirSeal, a valve-free trocar, and AnchorPort, a self-adjusting and self-anchoring trocar.</p></td> <td><p><escenic_non_breaking_space></escenic_non_breaking_space></p></td> <td><p>$7.5m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>SynapDx</b></p></td> <td><p>IVD</p></td> <td><p>SynapDx is developing a blood-based diagnostic test for autism spectrum disorders, which would identify children with the condition by age 36 months.</p></td> <td><p>North Bridge Venture Partners, General Catalyst Partners, Bain Capital Ventures</p></td> <td><p>$6m</p></td> <td><p>Series B </p></td> <td><p>$15m</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>InSightec</b></p></td> <td><p>Imaging</p></td> <td><p>InSightec's ExAblate platform combines MRI to visualise the target tissue or tumour and high-intensity focused ultrasound to ablate the target noninvasively. The technology is CE marked and FDA-approved for treating uterine fibroids, CE-marked for pain palliation of bone metasteses and being clinically assessed for other applications.</p></td> <td><p>GE Healthcare, Elbit Imaging, MediTech Advisors and other private investors</p></td> <td><p>$30.9m</p></td> <td><p>Series C</p></td> <td><p>$75.9m</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Wright Therapy Products</b></p></td> <td><p>Chronic disease management</p></td> <td><p>Wright markets home-use compression therapy devices for the management of lymphedema, venous insufficiency and also for use in the sports medicine markets.</p></td> <td><p>Undisclosed</p></td> <td><p>$3m </p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>MC10</b></p></td> <td><p>Electronics</p></td> <td><p>MC10 specialises in conformal electronics that stretch and bend seamlessly with the body's movements. The technology's medtech applications include making 'smart' interventional catheters that provide enhanced feedback to electrophysiologists and also for making 'smart' surgical sutures that can monitor wound healing.</p></td> <td><p>Medtronic and other strategic investors</p></td> <td><p>$10m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>23andMe</b></p></td> <td><p>IVD</p></td> <td><p>23andMe uses DNA anaysis technologies and web-based interactive tools to provide a Personal Genome Service ie personalised genetic research, to help individuals gain insight into inherited health traits.</p></td> <td><p>Private investors, Google Ventures, New Enterprise Associates, MPM Capital</p></td> <td><p>$50m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr>   </p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 15

VC Funding 2012
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 96814

<p> <table> <tbody> <tr> </tr> <tr> <td colspan="8" scope="row" widtd="101"><table> <tbody> <tr> <td colspan="4" scope="row" widtd="101">Are you betting on medtech's hottest areas?<a name="top" id="top"></a><br> <em>By Tina Tan, Editor</em><br> Find out who's investing in what with Clinica's venture/growth financing table, updated regularly with the latest investment deals.  </td> </tr> <tr> <td bgcolor="#666666" scope="row" widtd="101"><a href="http://www.clinica.co.uk/VC-Funding" class="optionsLink"><b>VC Funding 2013</b></a></td> <td bgcolor="#cccccc" scope="row" widtd="101"><b>VC Funding 2012</b></td> <td bgcolor="#666666" scope="row" widtd="101"><b><a href="http://www.clinica.co.uk/VC-Funding/_2011/" class="optionsLink">VC Funding 2011</a></b></td> <td bgcolor="#666666" scope="row" widtd="101"><b><a href="http://www.clinica.co.uk/freetrial/" class="optionsLink">FREE TRIAL</a></b></td> </tr> </tbody> </table></td> </tr> <tr> <td><a href="http://www.clinica.co.uk/business/"><img src="-/media/A41DB0E6789340E3BBE2BB586EBE4293.ashx" alt="Deals" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> <td scope="row" widtd="101"><div><a href="http://www.clinica.co.uk/business/manda/"><img src="-/media/1594690D6C314ABFA668C2F281D90DEC.ashx" alt="M&amp;A" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></div></td> <td><a href="http://www.clinica.co.uk/business/financials/"><img src="-/media/873669F6772642DC9C0C091A39B44486.ashx" alt="Financials" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> <td><div><a href="http://www.clinica.co.uk/business/funding/"><img src="-/media/B1AB1227A20C433897DB3C8B2F140E45.ashx" alt="Funding" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></div></td> <td><a href="http://www.clinica.co.uk/business/legal/"><img src="-/media/7D0516FC157A4E1F896F543962188904.ashx" alt="Legal" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> <td><a href="http://www.clinica.co.uk/business/start-upssmes/"><img src="-/media/66EE0878ED2E4CEC9D21449351C40077.ashx" alt="Start-ups &amp; SMEs" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> <td><a href="http://www.clinica.co.uk/business/marketmonitor/"><img src="-/media/808B4B2204F542438455FA3DB83F4C28.ashx" alt="Market Monitor" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> <td><a href="http://www.clinica.co.uk/ma2/"><img src="-/media/7183F022AB364B8C8C43E7EC13518288.ashx" alt="Google Map" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> </tr> <tr> <td scope="row" widtd="101"><div><a href="http://www.clinica.co.uk/business/" class="optionsLink">Deals</a></div></td> <td scope="row" widtd="101"><div><a href="http://www.clinica.co.uk/business/manda/" class="optionsLink">M&amp;A </a></div></td> <td><div><a href="http://www.clinica.co.uk/business/financials/" class="optionsLink">Financials</a></div></td> <td><div><a href="http://www.clinica.co.uk/business/funding/" class="optionsLink">Funding </a></div></td> <td><div><a href="http://www.clinica.co.uk/business/legal/" class="optionsLink">Legal</a></div></td> <td><div><a href="http://www.clinica.co.uk/business/start-upssmes/" class="optionsLink">Start-ups &amp; SMEs </a></div></td> <td><div><a href="http://www.clinica.co.uk/business/marketmonitor/" class="optionsLink">Market Monitor </a></div></td> <td><div><a href="http://www.clinica.co.uk/ma2/" class="optionsLink">Google Map: M&amp;A 2010 </a></div></td> </tr> </tbody> </table> <p> <p> <table> <tr bgcolor="#C5E2E2"> <th scope="col"><b>Company</b></th> <th scope="col"><b>Sector</b></th> <th scope="col"><b>Technology</b></th> <th scope="col"><b>Investors</b></th> <th scope="col"><b>Amount raised</b></th> <th scope="col"><b>Financing round</b></th> <th scope="col"><b>Total raised by company</b></th> <th scope="col"><b>Month</b></th> </tr> <tr> <td><p><b>Active Implants </b></p></td> <td><p>Orthopaedics</p></td> <td><p>Active Implants is developing the TriboFit Buffer hip implant, and the NUsurface meniscus knee implant</p></td> <td><p>Undisclosed</p></td> <td><p>$10.0m</p></td> <td><p>Series C</p></td> <td><p>At least $24.0m</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>AirXpanders </b></p></td> <td><p>Surgical</p></td> <td><p>AirXpanders is a tissue-expansion company focused on the area of breast cancer reconstruction</p></td> <td><p>Vivo Ventures; GBS Venture Partners; Prolog Ventures; Heron Capital; WTI </p></td> <td><p>$10.0m </p></td> <td><p>Series D</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Aria Diagnostics</b></p></td> <td><p>IVD</p></td> <td><p>Aria Diagnostics is developing prenatal tests based on the directed analysis of cell-free DNA in maternal blood. The company's primary focus is on the detection of foetal trisomies such as Trisomy 21, associated with Down's syndrome</p></td> <td><p>Meritech Capital Partners; Venrock; Domain Associates</p></td> <td><p>$52.7m</p></td> <td><p>Series C</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Avinger </b></p></td> <td><p>Cardiovascular / peripheral vascular</p></td> <td><p>Avinger is developing next-generation catheter-based technologies for the treatment of peripheral artery disease</p></td> <td><p>Undisclosed</p></td> <td><p>$22.5m</p></td> <td><p>Series C</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Carticept Medical </b></p></td> <td><p>Orthopaedics</p></td> <td><p>Carticept Medical is developing and commercialising products for the treatment of osteoarthritis or cartilage damage. Its Navigator Delivery System is a computer-controlled, infusion system to automate and improve the efficiency of fluid or medication administration, and the Cartiva Synthetic Cartilage Implant is designed to replace or repair worn or damaged cartilage</p></td> <td><p>Domain Associates; New Enterprise Associates; SonoSite</p></td> <td><p>$10.0m</p></td> <td><p>Series C</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Clearside Biomedical </b></p></td> <td><p>Drug delivery / Ophthalmology</p></td> <td><p>Clearside is developing a micro-needle to administer drugs to the back of the eye and retina</p></td> <td><p>Undisclosed </p></td> <td><p>$4.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>ConforMIS </b></p></td> <td><p>Orthopaedics</p></td> <td><p>ConforMIS is developing and commercialising medical devices for osteoarthritis treatment and joint damage</p></td> <td><p>AGC Equity Partners; Axel Johnson</p></td> <td><p>$89.0m</p></td> <td><p>Series E</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Corinthian Ophthalmic </b></p></td> <td><p>Drug delivery / Ophthalmology</p></td> <td><p>Corinthian is developing new delivery methods to administer drugs to the eye</p></td> <td><p>Undisclosed </p></td> <td><p>$3.25m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>CytoPherx </b></p></td> <td><p>Inflammation</p></td> <td><p>CytoPherx is developing and commercialising a cytopheresis system, which is used to sequester and deactivate leukocytes in patient with kidney injury</p></td> <td><p>Early Stage Partners; ONSET Ventures; Capital Midwest Fund</p></td> <td><p>$34.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Glysure </b></p></td> <td><p>Patient monitoring</p></td> <td><p>Glysure is developing in-hospital continuous blood glucose monitoring systems</p></td> <td><p>Morningside Venture; Amadeus Capital Partners; Chester Investments; Delta Partners</p></td> <td><p>$10.9m</p></td> <td><p>Series C</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>InCytu </b></p></td> <td><p>Biomaterials</p></td> <td><p>InCytu is developing Cellarium, a biopolymer scaffold to accelerate healing and enhance tissue regeneration</p></td> <td><p>Undisclosed </p></td> <td><p>$1.86m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>KeraNetics </b></p></td> <td><p>Biomaterials</p></td> <td><p>KeraNetics uses purifed keratin proteins for use in therapeutic and research applications</p></td> <td><p>Undisclosed </p></td> <td><p>$4.7m (of a planned $7.0m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>LensAR</b></p></td> <td>  <p>Ophthalmology</p></td> <td><p>LensAR is focused on the development and commercialisation of a next-generation laser and 3D-imaging technology for use in refractive cataract surgery</p></td> <td><p>Aisling Capital; Florida Growth Fund</p></td> <td><p>$24.05m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>MC10 </b></p></td> <td><p>Medical electronics</p></td> <td><p>MC10 is developing its conformal electronics platform for use in medical equipment and devices</p></td> <td><p>Aberdare Ventures</p></td> <td><p>$2.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Mevion Medical Systems </b></p></td> <td><p>Oncology</p></td> <td><p>Mevion Medical Systems is a radiation therapy company focused on the treatment of cancer</p></td> <td><p>ProQuest Investments; Caxton Heath Life Sciences; Venrock; CHL Medical Partners</p></td> <td><p>$45.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Natera</b></p></td> <td><p>IVD</p></td> <td><p>Natera develops tests for preimplantation genetic diagnosis performed during in-vitro fertilisation</p></td> <td><p>Lightspeed Venture Partners; Claremont Creek Ventures; Sequoia Capital</p></td> <td><p>$20.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>NeuroLogica </b></p></td> <td><p>Imaging</p></td> <td><p>NeuroLogica is developing BodyTom, a portable computed tomography imaging system  </p></td> <td><p>Gordon Charitable Remainder Trust</p></td> <td><p>$12.0m </p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Oxford Cancer Biomarkers </b></p></td> <td><p>Biomarkers / Personalised medicine / Cancer</p></td> <td><p>Oxford Cancer Biomarkers is focused on the development and commercialisation of predictive cancer biomarkers</p></td> <td><p>Quintiles</p></td> <td><p>&pound;3.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>ProteoMediX </b></p></td> <td><p>IVD / Cancer</p></td> <td><p>ProteoMedix is developing biomarker diagnostics for the detection of prostate cancer</p></td> <td><p>Altos Venture; BioValley Business Angels Club; Zurcher Kantonalbank</p></td> <td><p>CHF2.6m</p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>SEA Medical Systems </b></p></td> <td><p>Patient monitoring</p></td> <td><p>SEA Medical is developing devices to identify drugs, concentrations, and diluents in IV fluids, and measure flow rates and cumulative dose during IV administration</p></td> <td><p>JK&amp;B Capital</p></td> <td><p>$3.0m </p></td> <td><p>Series B</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>Solx</b></p></td> <td>  <p>Ophthalmology</p></td> <td><p>Solx is focused on the management and surgical treatment of glaucoma</p></td> <td><p>Undisclosed </p></td> <td><p>$3.25m (of a planned $9.0m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>SPR Therapeutics </b></p></td> <td><p>Neurology</p></td> <td><p>SPR Therapeutics is developing its Smartpatch and MicroPulse Neurostimulation pain-relief devices</p></td> <td><p>NDI Medical; JumpStart </p></td> <td><p>$2.2m (of a planned $2.5m financing round)</p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>Jan</p></td> </tr> <tr> <td><p><b>ALung Technologies </b></p></td> <td><p>Respiratory </p></td> <td><p>ALung is developing the Hemolung Respiratory Assist device, to remove the need to keep patients in respiratory distress sedated on mechanical ventilators</p></td> <td><p>Undisclosed</p></td> <td><p>$10.0m</p></td> <td><p>Series B</p></td> <td><p>At least $25.0m</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Apollo Endosurgery </b></p></td> <td><p>Surgical</p></td> <td><p>Apollo Endosurgery develops therautic endoscopy devices such as its OverStitch Endoscopic Suturing System and FlexShears Endoscopic Scissors </p></td> <td><p>Novo AS; Remeditex Ventures; CPMG; PTV Sciences; HIG BioVentures</p></td> <td><p>$47.6m</p></td> <td><p>undisclosed</p></td> <td><p>At Least $59.1m</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>CardioInsight Technologies </b></p></td> <td><p>Imaging / <br> Cardiovascular / peripheral vascular</p></td> <td><p>CardioInsight is commercialising its ECVUE 3D cardiac mapping system </p></td> <td><p>Undisclosed</p></td> <td><p>$7.5m</p></td> <td><p>Series C</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>CartiHeal</b></p></td> <td><p>Orthopaedics</p></td> <td><p>CartiHeal is developing its Agili-C cartilage regeneration device for use in arthroscopic procedures</p></td> <td><p>Accelmed; Access Medical Ventures</p></td> <td><p>$5.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Cayenne Medical </b></p></td> <td><p>Orthopaedics</p></td> <td><p>Cayanne Medical is commercialising its AperFix II, CrossFix II and iFix systems for the treatment of sport-related orthopaedic injuries</p></td> <td><p>Undisclosed</p></td> <td><p>$10.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Cervilenz </b></p></td> <td><p>Reproductive medicine</p></td> <td><p>Cervilenz is developing a disposable medical device that measures cervical length to help identify and manage pregnant women at high risk for preterm birth</p></td> <td><p>Undisclosed</p></td> <td><p>$2.0m (of a planned $3.0m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>At least $6.0m</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Checkpoint Surgical </b></p></td> <td><p>Surgical</p></td> <td><p>Checkpoint is developing the CHECKPOINT Stimulator/Locator, a single-use, sterile device intended to locate and identify nerves and to test nerve and muscle excitability</p></td> <td><p>Undisclosed</p></td> <td><p>$1.7m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Dymedix Diagnostics </b></p></td> <td><p>Patient monitoring</p></td> <td><p>Dymedix is focused on the development of sleep sensors for use in clinical sleep studies</p></td> <td><p>Undisclosed</p></td> <td><p>$2.15m (of a planned $4.2m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>GeneWeave Biosciences </b></p></td> <td><p>IVD</p></td> <td><p>GeneWeave is developing its GeneScout platform for the detection of pathogens</p></td> <td><p>Decheng Capital; Claremont Creek Ventures; X/Seed Capital</p></td> <td><p>$12.0m </p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Integrated Diagnostics</b></p></td> <td><p>IVD</p></td> <td><p>Integrated Diagnostics is developing blood-based molecular diagnostics for the early detection of cancer and Alzheimer's disease</p></td> <td><p>InterWest Partners; The Grand Duchy of Luxembourg; Wellcome Trust</p></td> <td><p>$10.0m</p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Nuclea Biotechnologies </b></p></td> <td><p>Biomarkers / IVD / Cancer</p></td> <td><p>Nuclea is a translational medicine company focused on the discovery of biomarkers and in vitro companion diagnostic assays. The company's DecisionDx platform is being used to develop diagnostics for use in therapeutic and medical imaging applications for oncology and other indications </p></td> <td><p>Undisclosed</p></td> <td><p>$3.4m</p></td> <td><p>Series B</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>On-Q-ity</b></p></td> <td><p>Personalised medicine / Cancer</p></td> <td><p>On-Q-ity is focused on the development of pesonalised diagnostics for the detection and treatment of cancer</p></td> <td><p>Atlas Ventures; Mohr Davidow Ventures; Physic Ventures</p></td> <td><p>$5.0m</p></td> <td><p>Series B</p></td> <td><p>At least $31.0m</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Sense AS </b></p></td> <td><p>Patient monitoring</p></td> <td><p>Sense AS is developing accurate, non-invasive devices for the measurement of blood pressure</p></td> <td><p>SEED Capital; Vaekstfonden</p></td> <td><p>&euro;4.5m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Sequent Medical</b></p></td> <td><p>Surgical / Neurology</p></td> <td><p>Sequent Medical is developing catheter-based neurovascular devices for the treatment of intracranial aneurysms </p></td> <td><p>Delphi Ventures; Versant Ventures; Domain Associates; US Venture Partners </p></td> <td><p>$26.04m</p></td> <td><p>Series C</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>TriVascular </b></p></td> <td><p>Surgical</p></td> <td><p>TriVascular is developing the Ovation Abdominal Stent Graft, a device to be used in endovascular aortic repair</p></td> <td><p>Undisclosed</p></td> <td><p>$7.2m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>TruTouch Technologies </b></p></td> <td><p>Patient monitoring</p></td> <td><p>TruTouch is commercialising a non-invasive biometric intoxication detection system</p></td> <td><p>iTulip; Launchpad Venture Group; Verge Fund; Jerome Capital</p></td> <td><p>$3.0m (of a planned $5.0m financing round)</p></td> <td><p>Series B</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Vascular Magnetics </b></p></td> <td><p>Drug delivery</p></td> <td><p>Vascular Magnetics is developing a magnetically-targeted drug delivery system for the treatment of peripheral artery disease</p></td> <td><p>Devon Park Bioventures</p></td> <td><p>$7.0m</p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Velomedix</b></p></td> <td><p>Cardiovascular / peripheral vascular</p></td> <td><p>Velomedix is focused on the development of mild therapeutic hypothermia systems for the protection of patients from the effects of cardiovascular insults</p></td> <td><p>Undisclosed</p></td> <td><p>$10.2m</p></td> <td><p>Series B</p></td> <td><p>undisclosed</p></td> <td><p>Feb</p></td> </tr> <tr> <td><p><b>Alcyone Lifesciences</b></p></td> <td><p>Neurology</p></td> <td><p>Alcyone Lifesciences is focused on developing treatments for chronic neurological conditions</p></td> <td><p>Undisclosed</p></td> <td><p>$1.86m (of a planned $2.0m financing round) </p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>BodyMedia </b></p></td> <td><p>Patient monitoring</p></td> <td><p>BodyMedia is developing its BodyMedia FIT system to monitor user's activity, calorie output and sleep patterns</p></td> <td><p>Undisclosed</p></td> <td><p>$2.73m (of a planned $10.0m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Genalyte </b></p></td> <td><p>IVD</p></td> <td><p>Genalyte is developing its Multiplex Maverick system with Microring Sensor Technology for autoimmune and immunoassay applications</p></td> <td><p>Redmile Group; Claremont Creek Ventures</p></td> <td><p>$11.8m</p></td> <td><p>Series B</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Icon Medical </b></p></td> <td><p>Cardiovascular / peripheral vascular</p></td> <td><p>Icon Medical is developing a cardiac stent</p></td> <td><p>Undisclosed</p></td> <td><p>$2.7m (of a planned $5.0m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>ImaginAb </b></p></td> <td><p>IVD</p></td> <td><p>ImaginAb is developing in vivo imaging agents for Positron Emission Tomography (PET) based on antibody fragment technology</p></td> <td><p>Cycad Group; Merieux Developpement; Momentum Biosciences; Nextech Invest; Novartis Venture Funds</p></td> <td><p>$12.5m</p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>InControl Medical </b></p></td> <td><p>Urology</p></td> <td><p>InControl is developing and commercialising InTone, a device to treat female incontinence</p></td> <td><p>Undisclosed</p></td> <td><p>$3.2m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Innovative Biosensors</b></p></td> <td><p>IVD</p></td> <td><p>Innovative Biosensors develops and manufactures rapid testing systems for the detection of pathogens</p></td> <td><p>Undisclosed</p></td> <td><p>$1.5m (of a planned $2.7m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Life Core Technologies </b></p></td> <td><p>Neurology</p></td> <td><p>Life Core is developing its EXCEL<escenic_non_breaking_space></escenic_non_breaking_space>Cerebral Cooling System, a unique single use device to induce mild cerebral hypothermia to protect patients from ischaemic and reperfusion injury effects of cardiac arrest, heart attack, stroke and traumatic brain injury</p></td> <td><p>Undisclosed</p></td> <td><p>$1.0m</p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Molecular Detection </b></p></td> <td><p>IVD</p></td> <td><p>Molecular Detection is developing and commercialising a portfolio of Detect-Ready molecular diagnostic tests for the detection of infectious diseases such as MRSA</p></td> <td><p>MentorTech Ventures; Rood Hood Ventures; Elm Spring Holdings; Mid-Atlantic Angel Group</p></td> <td><p>$1.5m</p></td> <td><p>undisclosed</p></td> <td><p>At least $6.2m</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Myoscience</b></p></td> <td><p>Aesthetic medicine</p></td> <td><p>Myoscience is developing its toxin-free focused cold therapy platform technology for the treatment of forehead wrinkles</p></td> <td><p>Accuitive Medical Ventures; American Equities Overseas; Medicis Capital Group; Nexus Medical Partners; Saratoga Ventures; Valiance Capital</p></td> <td><p>$33.0m</p></td> <td><p>Series D</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>NLT Spine </b></p></td> <td><p>Orthopaedics</p></td> <td><p>NLT Spine is developing and commercialising its PROW LIF lumbar fusion product line for treating degenarative spinal conditions</p></td> <td><p>Accelmed; Peregrine Ventures</p></td> <td><p>$5.7m</p></td> <td><p>undisclosed</p></td> <td><p>$14.5m</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>OpGen </b></p></td> <td><p>Genomics</p></td> <td><p>OpGen is a whole-genome analysis company that provides tools for sequence assembly and finishing, microbial strain comparison and species characterisation</p></td> <td><p>Harris &amp; Harris Group; Cross Creek Capital; Highland Capital Partners; Versant Ventures; jVen Capital; CHL Medical Partners</p></td> <td><p>Up to $17.0m</p></td> <td><p>undisclosed</p></td> <td><p>At least $62.6m</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Promethera Biosciences </b></p></td> <td><p>Cell therapy</p></td> <td><p>Promethera Biosciences is developing HepaStem, a cell therapy based on the use of allogeneic stem cells from healthy livers, for the treatment of a wide range of liver diseases</p></td> <td><p>Boehringer Ingelheim Venture Fund; Shire; Mitsui Global Investment; ATMI; Sambrinvest</p></td> <td><p>Euro17.0m</p></td> <td><p>Series B</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Provista Diagnostics </b></p></td> <td><p>IVD / Cancer</p></td> <td><p>Provista Diagnostics is commercialising biomarker-based diagnostic tests for the detection of breast, ovarian and lung cancer</p></td> <td><p>Undisclosed</p></td> <td><p>$4.51m (of a planned $4.95m financing round)</p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>Mar</p></td> </tr> <tr> <td><p><b>Quotient Biodiagnostics </b></p></td> <td><p>IVD / Haematology</p></td> <td><p>Quotient Biodiagnostics is focused on providing immunohaematology products to hospitals and blood banks</p></td> <td><p>Galen Partners</p></td> <td><p>$11.2m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>Mar</p></td> </tr> <tr> <td><p><b>Relievant Medsystems </b></p></td> <td><p>Orthopaedics</p></td> <td><p>Relievant Medsystems is developing its Intracept Ablation System for the treatment of chronic axial low back pain</p></td> <td><p>New Enterprise Associates; Canaan Partners; Emergent Medical Partners; Morgenthaler Ventures; ONSET Ventures</p></td> <td><p>$30.0m</p></td> <td><p>Series D</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Sapheon </b></p></td> <td><p>Surgical</p></td> <td><p>Sapheon is commercialising a minimally-invasive closure system for treating varicose veins</p></td> <td><p>Undisclosed</p></td> <td><p>$1.3m (of a planned $5.0m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Sientra </b></p></td> <td><p>Biomaterials</p></td> <td><p>Sientra is commercialising its portfolio of Silimed silicone gel breast implants</p></td> <td><p>Abingworth; Clarus Ventures; OrbiMed Advisors</p></td> <td><p>$65.0m</p></td> <td><p>Series C</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Solace Therapeutics </b></p></td> <td><p>Surgical / Urology</p></td> <td><p>Solace Therapeutics is developing the AttenueX Balloon device for insertion into the bladder via a catheter, for the treatment of stress incontinence and involuntary urinary leakage</p></td> <td><p>Undisclosed</p></td> <td><p>$7.0m (of a planned $20.0m financing round)</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Tepha </b></p></td> <td><p>Biomaterials</p></td> <td><p>Tepha produces absorbable polymer biomaterials for the manufacture of surgical sutures and meshes</p></td> <td><p>Undisclosed</p></td> <td><p>$11.3m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Thermedical</b></p></td> <td><p>Surgical</p></td> <td><p>Thermedical is developing a Saline Enhanced Radio Frequency ablation system for excising solid tissue cancers and treating cardiac arrhythmias</p></td> <td><p>Undisclosed</p></td> <td><p>$1.5m</p></td> <td><p>Series A </p></td> <td><p>undisclosed</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>ViewRay </b></p></td> <td><p>Imaging</p></td> <td><p>ViewRay is focused on developing a system to deliver MRI-guided radiotherapy, providing continuous soft-tissue imaging during treatment</p></td> <td><p>Siemens Venture Capital; Aisling Capital; Fidelity Biosciences; Kearny Venture Partners; OrbiMed Advisors</p></td> <td><p>$25.0m (final tranche of a $45.0m financing round)</p></td> <td><p>Series C</p></td> <td><p>At least $60.0m</p></td> <td><p>March</p></td> </tr> <tr> <td><p><b>Aggredyne</b></p></td> <td><p>IVD</p></td> <td><p>Blood platelet function testing; the first product from Aggredyne's platform is the AggreGuide A-100 laser-light scattering platelet aggregometer for analysing a patient's responsiveness to anti-platelet medication</p></td> <td><p>Undisclosed</p></td> <td><p>$3m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Aleva Neurotherapeutics</b></p></td> <td><p>Neurology</p></td> <td><p>Deep brain stimulation implants based on Aleva's microDBS technology to treat Parkinson's and other central nervous system disorders</p></td> <td><p>Banexi Ventures Partners, BioMedInvest, BB Biotech Ventures III, Initiative Capital Romandie and private investors</p></td> <td><p>CHF4m</p></td> <td><p>Series B</p></td> <td><p>&euro;12.8m</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>AlloCure</b></p></td> <td><p>Cellular therapy</p></td> <td><p>Stem cell therapy for treating kidney disease</p></td> <td><p>Lundbeckfond Ventures, SV Life Sciences, Novo</p></td> <td><p>$25m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Arterial Remodeling Technologies </b></p></td> <td><p>Cardiovascular</p></td> <td><p>Bioresorbable coronary stent</p></td> <td><p>Undisclosed</p></td> <td><p>$2.9m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Cadence Biomedical</b></p></td> <td><p>Orthopaedic/ Rehabilitation</p></td> <td><p>Kinetic orthosis medical devices that help people with severe mobility disabilities walk. The devices provide stability and movement assistance to weakened muscles without the use of powered mechanisms </p></td> <td><p>HealthTech Capital, Sand Hill Angels, Tech Coast Angel, ACE Fund, Frontier Angel Fund, WINGs, Alliance of Angels and Keiretsu Forum Northwest</p></td> <td><p>$1.1m</p></td> <td><p>Series A2</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>CyVek</b></p></td> <td><p>IVD</p></td> <td><p>An integrated test system for performing bioassays, molecular diagnostics and immunodiagnostics in drug discovery and point-of-care applications</p></td> <td><p>Undisclosed</p></td> <td><p>$3m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Good Start Genetics</b></p></td> <td><p>IVD</p></td> <td><p>Pre-conception carrier screening tests</p></td> <td><p>OrbiMed Advisors, Safeguard Scientifics, SV Life Sciences</p></td> <td><p>$14m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Imricor Medical Systems</b></p></td> <td><p>Cardiovascular</p></td> <td><p>The Vision MR EP ablation catheter is an MRI-compatible electrophysiology tool for performing cardiac ablation to treat arrhythmia. </p></td> <td><p>Undisclosed</p></td> <td><p>$4m</p></td> <td><p>Undisclosed</p></td> <td><p>$10m</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>InCellDx</b></p></td> <td><p>IVD</p></td> <td><p>Molecular diagnostic tests for detecting hepatitis, cervical cancer, breast cancer, HIV/AIDS and organ transplant rejection</p></td> <td><p>Bio-Reference Laboratories</p></td> <td><p>$6m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Inogen</b></p></td> <td><p>Respiratory/ Home care</p></td> <td><p>Inogen One is a home-based, portable oxygen therapy that is used particularly by patients suffering from chronic obstructive pulmonary disease</p></td> <td><p>Versant Ventures, Accuitive Medical Ventures, Avalon Ventures and Arboretum Ventures</p></td> <td><p>$20m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Life Core Technologies</b></p></td> <td><p>Neurovascular</p></td> <td><p>Excel Cerebral Cooling system that applies therapeutic hypothermia to reduce brain damage to patients who have suffered heart attack, stroke or traumatic brain injury</p></td> <td><p>Private and angel investors</p></td> <td><p>$1m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>MolecularMD</b></p></td> <td><p>IVD</p></td> <td><p>Companion diagnostics for targeted cancer therapies under development </p></td> <td><p>Ballast Point Ventures, Nextech Invest</p></td> <td><p>$6m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Obalon Therapeutics</b></p></td> <td><p>Bariatric surgery</p></td> <td><p>A device that occupies the gastrointestinal space to promote weight loss</p></td> <td><p>Undisclosed</p></td> <td><p>$1.5m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>OvaScience</b></p></td> <td><p>Cellular therapy</p></td> <td><p>Fertility treatment based on egg precursor cells</p></td> <td><p>General Catalyst, Bessemer Venture Partners, Longwood Fund, BBT Capiral Management Advisors, Cycad Group, Hunt BioVentures, RA Capital, unnamed large global institutional investor</p></td> <td><p>$37m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>SynGen</b></p></td> <td><p>Regenerative medicine</p></td> <td><p>SynGen-1000 stem cell harvesting system, initially targeted for use by cord blood banks</p></td> <td><p>Bay City Capial</p></td> <td><p>$5m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>Vivia Biotech</b></p></td> <td><p>IVD</p></td> <td><p>Personalised medicine in haematologic cancers</p></td> <td><p>Bioanal&iacute;tica Inversiones and other public investment funds</p></td> <td><p>&euro;7.2m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>April</p></td> </tr> <tr> <td><p><b>ArcDia </b></p></td> <td><p>IVD</p></td> <td><p>The mariPOC is a multianalyte point-of-care test to detect respiratory tract infections</p></td> <td><p>Lifeline Ventures, Biothom, Veraventure and other private investors</p></td> <td><p>&euro;2.7m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>AssureRx Health</b></p></td> <td><p>IVD</p></td> <td><p>GeneSightRx is a line of genetic test that measure and analyse genetic variants affecting response to psychiatric medications in individual patients</p></td> <td><p>Four Rivers Group, Claremont Creek Ventures, Sequoia Capital, Cincinnati Children's Hospital Medical Center, Mayo Clinic, CincyTech, Allos Ventures, jVen Capital and Alafi Capital </p></td> <td><p>$12.5m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>AxioMed Spine</b></p></td> <td><p>Orthopaedics</p></td> <td><p>Spinal disc implants, including the Freedom lumbar disc, to treat degenerative spinal diseases and restore spinal function</p></td> <td><p>CID Equity Partners, Early Stage Partners, Ivnestor Growth Capital, MB Venture Partners, Primus Capital Funds, Reservoir Venture Partners, Charter Oak Equity, Blue Chip and Thomas, McNerny &amp; Partners</p></td> <td><p>$5m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>ClearCount Medical Solutions</b></p></td> <td><p>OR safety</p></td> <td><p>The SmartSponge is an RFID-enabled system that allows automated counting of surgical sponges and prevent them being left inside the patient</p></td> <td><p>Draper Triangle Ventures and other investors</p></td> <td><p>$1.5m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>EndoSphere</b></p></td> <td><p>Bariatric surgery</p></td> <td><p>The Satisphere system is a device inserted into the patient endoscopically and designed to treat obesity by regulating the patient's appetite and satiety by using the body's natural physiology</p></td> <td><p>Broadline Capital, Glengary, North Coast Angel Fund, Ohio TechAngel Fund and Queen City Angels</p></td> <td><p>$3.1m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Flowonix Medical</b></p></td> <td><p>Drug delivery</p></td> <td><p>The Prometra pump is a programmable implantable drug pump</p></td> <td><p>RFT Investment Company, OmniCapital Fund, Clarus Ventures and other investors</p></td> <td><p>$25m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Healthsense</b></p></td> <td><p>Patient monitoring</p></td> <td><p>Wireless 'passive' medical devices designed for remote home monitoring of elderly patients</p></td> <td><p>Radius Ventures, Ziegler HealthVest Partners and The Ziegler Companies</p></td> <td><p>$13.7m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Inspire Medical Systems</b></p></td> <td><p>Neurology/Respiratory</p></td> <td><p>The Inspire upper airway stimulation therapy employs neurostimulation to treat moderate to severe obstructive sleep apnea</p></td> <td><p>Medtronic, TGap Ventures, Kleiner Perkins Caufield &amp; Byers, US Venture Partners, Synergy Life Science Partners and GDN Hodings</p></td> <td><p>$14.5m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>i-Optics </b></p></td> <td><p>Ophthalmology</p></td> <td><p>Eye imaging devices including the EasyScan fundus camera and the Cassini cornea topographer</p></td> <td><p>Aescap Venture, De Hoge Dennen and other family funds and private investors</p></td> <td><p>&euro;6.7m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Kona Medical</b></p></td> <td><p>Neurovascular/ Surgery</p></td> <td><p>An ultrasound-based systems for carrying out renal denervation to treat hypertension in drug-resistant patients</p></td> <td><p>Essex Woodlands, Domain Associates, Morgenthaler Ventures and BioStar Ventures</p></td> <td><p>$30m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Mitralign</b></p></td> <td><p>Cardiovascular</p></td> <td><p>Percutaneous mitral valve repair</p></td> <td><p>Forbion Capital Partners, Saints Venture Capital, Oxford Bioscience Partners, Triathlon Medical Ventures, Medtronic, Johnson &amp; Johnson Development, Orchestra Medical Venutres, Oakwood Medical Invesors, Palisade Capital Management and Giza Venture Capital</p></td> <td><p>$35m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Monteris Medial</b></p></td> <td><p>Neurosurgery</p></td> <td><p>The NeuroBlate system is an MRI-guided, laser-based neurosurgical ablation system for difficult-to-treat brain tumours</p></td> <td><p>Business Development Bank of Canada, SWMF Life Science Fund and Richardson GMP</p></td> <td><p>$9m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Neuronetics</b></p></td> <td><p>Neurology</p></td> <td><p>The NeuroStar system offers transcranial magnetic stumylation to treat major depression</p></td> <td><p>Polaris Venture Partners, Pfizer Venture Investments, Investor Growth Capital, New Leaf Venture Partners, Interwest Partners, Three Arch Partners, Quaker BioVentures and Onset Ventures</p></td> <td><p>$30m</p></td> <td><p>Series E</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Novacyt</b></p></td> <td><p>IVD</p></td> <td><p>A fully automated  liquid-based cytology system for cervical cancerscreening. The system consists of the NovaPrep processor and the NovaPrep Vial test</p></td> <td><p>Arkeon Gestion and private investors</p></td> <td><p>&euro;1.5m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>OrthoSensor</b></p></td> <td><p>Orthopaedics</p></td> <td><p>The OrthoSensor knee balancer is embedded with sensors to help surgeons better place and fit knee implants in the patient</p></td> <td><p>Ziegler Medtech Capital Advisors</p></td> <td><p>$15m</p></td> <td><p>Series B2</p></td> <td><p>$42m</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Oxford Nanopore Technologies</b></p></td> <td><p>Molecular diagnostics</p></td> <td><p>MinION is a gene sequencing device the size of a USB stick</p></td> <td><p>Existing investors</p></td> <td><p>&pound;31.4m</p></td> <td><p>Undisclosed</p></td> <td><p>&pound;105.4m</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Pathfinder Therapeutics</b></p></td> <td><p>Imaging/Surgery</p></td> <td><p>The Explorer is an image-guided surgery system used in cancer treatment procedures, such as resection or ablation</p></td> <td><p>Undisclosed</p></td> <td><p>$5.3m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Regentis Biomaterials</b></p></td> <td><p>Regenerative medicine</p></td> <td><p>Gelrin is a biodegradable hydrogel platform designed for tissue regeneration applications; GelrinC is designed to treat articular cartilage lesions </p></td> <td><p>Royal DSM, Crossroad Rund, Medica Venture Partners, SCPVitalife and the Technion Investment Opportunities Fund</p></td> <td><p>$10m</p></td> <td><p>Series C</p></td> <td><p>$18m</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Sonitus Medical</b></p></td> <td><p>ENT</p></td> <td><p>The SoundBite hearing system is a non-surgical and removable hearing device that transmits sound via the teeth</p></td> <td><p>Abingworth, Aberdare Ventures, Arboretum Ventures, In-Q-Tel, Novartis Venture Funds, RWI Ventures</p></td> <td><p>$25m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Vibrynt</b></p></td> <td><p>Bariatric surgery</p></td> <td><p>The Vibrynt Prevail implant is a device that limits the amount of food that enters the stomach by restricting expansion </p></td> <td><p>Delphi Ventures, New Enterprise Associates, Texas Pacific Group and other investors</p></td> <td><p>Around $2.75</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>Zyga Technology</b></p></td> <td><p>Orthopaedics</p></td> <td><p>Minimally invasive spinal devices such as the SImmetry spinal fusion system and the Glyder facet resurfacing system to treat facetogenic pain caused by degeneration in the joints in the back of the spine</p></td> <td><p>Versant Ventures, Split Rock Partners, Domain Associates and MB Ventures</p></td> <td><p>$25m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>May</p></td> </tr> <tr> <td><p><b>MedShape </b></p></td> <td><p>Orthopaedics</p></td> <td><p>MedShape is developing a range of orthopaedic devices</p></td> <td><p>GE Capital</p></td> <td><p>$3.0m</p></td> <td><p>undisclosed</p></td> <td><p>undisclosed</p></td> <td><p><escenic_non_breaking_space></escenic_non_breaking_space></p></td> </tr> <tr> <td><p><b>Ablative Solutions</b></p></td> <td><p>Neurology</p></td> <td><p>PVRD (PeriVascular Renal Denervation) is a proprietary technique for managing drug-resistant hypertension</p></td> <td><p>BioStar Ventures, Michigan Accelerator Fund and angel investors</p></td> <td><p>$5.3m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Agendia</b></p></td> <td><p>IVD</p></td> <td><p>Symphony is a suite of tests that offer breast cancer patients more personalised medicine. It includes the MammaPrint, that tests recurrence of breast cancer, BluePrint, a molecular subtyping assay, TargetPrint, an ER/PR/HER2 expression assay and TehraPrint an alternative therapy selection assay. </p></td> <td><p>Debiopharm Group, Van Herk Group, ING Corproate Investments, Breedinvest, Gilde Healthcare, Korys and other investors</p></td> <td><p>$65m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>AliveCor</b></p></td> <td><p>Patient monitoring</p></td> <td><p>Mobile ECG device</p></td> <td><p>Burril &amp; Company, Khosla Ventures</p></td> <td><p>$10.5m</p></td> <td><p>Series B</p></td> <td><p>$13.5m</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Aptus Endosystems</b></p></td> <td><p>Cardiovascular/ Peripheral vascular</p></td> <td><p>Fortevo endograft system is used for the endovascular repair of abdominal aortic aneurysms. The HeliFX aortic securement system helps to secure the sealing and fixing of the endograft to the aortic wall</p></td> <td><p>Synergy Life Science Partners, US Venture Partners and Longitude Capital Management</p></td> <td><p>$25m</p></td> <td><p>Series BB</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Astute Mediccal</b></p></td> <td><p>IVD</p></td> <td><p>Novel protein biomarker-based tests for detecting community and hospital-acquired acute conditions. Areas of focus include acute coronary syndromes, abdominal pain, cerebrovascular injury, kidney injury and sepsis</p></td> <td><p>MPM Capital, Kaiser Permanente Ventures, De Novo Ventures, Delphi Ventures, Domain Associates and Johnson &amp; Johnson Development Corporation</p></td> <td><p>$40.4m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Auxogyn</b></p></td> <td><p>IVD</p></td> <td><p>Eeva is a noninvastive test to evaluate embryo viability during in vitro fertilisation </p></td> <td><p>SR One, GlaxoSmithKline, Kleiner Perkins Caufield and Byres, TPG Biotech and Merck Serono Ventures</p></td> <td><p>$18m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Awarepoint</b></p></td> <td><p>Healthcare IT</p></td> <td><p>aware360&deg; Suite of real-time location systems are designed to manage and track hospitals' mobile assets, patients, personnel; also for patient monitoring, and workflows across healthcare facilities </p></td> <td><p>Kleiner Perkins Caufield &amp; Byers, Cardinal Partners, Venrock, Jafco Ventures, Avalon Ventures, New Leaf Venture Partners and Top Tier Capital Partners</p></td> <td><p>$14m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Benvenue Medical</b></p></td> <td><p>Orthopaedics</p></td> <td><p>Minimally invasive devices for treating degenerative disc disease and vertebral compression fractures. Kiva and Blazer are used for the latter application, and Luna is an interbody spacer system for spinal fusion</p></td> <td><p>Versant Ventures, DeNovo Ventures, Domain Associates, Technology Partners </p></td> <td><p>$25m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>BioBehavioural Diagnostics</b></p></td> <td><p>Neurology/ Diagnostics</p></td> <td><p>Quotient ADHD system is designed to objectively measure brain functions and help diagnose attention-deficit hyperactivity disorder</p></td> <td><p>Undisclosed</p></td> <td><p>$5.2m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Biomimedica</b></p></td> <td><p>Orthopaedics</p></td> <td><p>GRADION total cartilage replacement technology is synthetic cartilage for joint repairs</p></td> <td><p>Troika Ventures, Biedermann Motech, Emergent Medical Partners  and Asset Management Ventures</p></td> <td><p>$11.9m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>CD Diagnostics</b></p></td> <td><p>IVD</p></td> <td><p>Joint fluid assays</p></td> <td><p>Undisclosed</p></td> <td><p>$5m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>CellScope</b></p></td> <td><p>Healthcare IT/ Diagnostics</p></td> <td><p>Smartphone peripheral devices that enable the user to turn their smartphones into diagnostic tools. The first -enabled otoscope to diagnose ear infections in children</p></td> <td><p>Khosla Ventures </p></td> <td><p>$1m</p></td> <td><p>Seed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Cohera Medical</b></p></td> <td><p>Surgery</p></td> <td><p>Absorbable surgical adhesives and sealants. Cohera's first product is TissueGlu surgical adhesive; the company is also developing the FlexSil surgical sealant for bowel repair</p></td> <td><p>Private investors</p></td> <td><p>$8.4m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>EndoGastric Solutions</b></p></td> <td><p>Surgery</p></td> <td><p>EsophyX is a device used in combination with transoral incisionless fundoplication to restore gastroesophageal valve and restore its ability to block acid reflux</p></td> <td><p>Advanced Technology Ventures, Canaan Partners, Chicago Growth Partners, De Novo Ventures, Foundation Medical, Oakwood Medical Investors and Radius Ventures</p></td> <td><p>$13m</p></td> <td><p>Series F2</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Grove Instruments</b></p></td> <td><p>Patient monitoring</p></td> <td><p>Blood glucose monitoring</p></td> <td><p>Private investors</p></td> <td><p>$2.5m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>HyperBranch Medical Technology</b></p></td> <td><p>Surgery</p></td> <td><p>Polymer-based surgical sealants for use in range of applications including ophthalmic, dural, hernia repair, spinal and cardiovascular</p></td> <td><p>Undisclosed</p></td> <td><p>$1.7m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Invuity</b></p></td> <td><p>Surgery</p></td> <td><p>The company incorproates its proprietary Eigr illumination technology into advanced access systems used in various minimally invasive surgical procedures </p></td> <td><p>Valence Advantage Life Sciences Fund II, Kleiner Perkins Caufield &amp; Byres and InterWest Partners</p></td> <td><p>$25m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>JustRight Surgical</b></p></td> <td><p>Surgery</p></td> <td><p>Low-power tissue sealing device</p></td> <td><p>Undisclosed</p></td> <td><p>$6.6m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>NeuroSave</b></p></td> <td><p>Neurovascular</p></td> <td><p>Therapeutic hypothermia system for treating patients after cardiac arrest or traumatic brain surgery</p></td> <td><p>Undisclosed</p></td> <td><p>$1.5m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>NexDx</b></p></td> <td><p>IVD</p></td> <td><p>Molecular diagnostic tests for personalised medicine in rheumatoid arthritis and other autoimmune diseases</p></td> <td><p>City Hill Ventures</p></td> <td><p>$2.1m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>NovaTract Surgical</b></p></td> <td><p>Surgery</p></td> <td><p>Laparoscopic devices for minimally invasive surgery. NovaTract's first product is an organ retraction device that allows surgeons to carry out more easily single-incision and natural orific transluminal endoscopic surgery devices</p></td> <td><p>Undisclosed</p></td> <td><p>$3.2m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Oxford Immunotec</b></p></td> <td><p>IVD</p></td> <td><p>T-SPOT TB is an interferon-gamma release assay which detects latent TB infection. It is the first test from Oxford Immunotec's T-SPOT platform for directly quantifying antigen-specific T cells</p></td> <td><p>Imperial Innovations, Invesco Perpetual, Clarus, New Leaf, DFJ Esprit, Wellington, SPARK Ventures, Dow Chemical Company, NTEC, Kaiser Permanente Ventures and the University of Oxford</p></td> <td><p>$28m</p></td> <td><p>Series E</p></td> <td><p>$110m</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>ProTip </b></p></td> <td><p>ENT</p></td> <td><p>ENTegral is a permanent implant to replace the larynx in patients who have undergone total laryngectomy</p></td> <td><p>Seventure, Fonds Lorrain des Materiaux, the Berchet family-office, Alsace Amorcage and other private investors</p></td> <td><p>$4.7m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>SentreHEART </b></p></td> <td><p>Surgery</p></td> <td><p>The Lariat suture delivery device is designed for the remote delivery of a pre-tied suture loop for closing soft tissue wounds in catheter-based procedures</p></td> <td><p>VivoVentures, US Venture Partners and Prospect Ventures</p></td> <td><p>$26m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Seventh Sense Biosystems</b></p></td> <td><p>Blood collection/IVD</p></td> <td><p>Touch Activated Phlebotomy is a painless blood sampling platform. The initial application is for use in the field of in vitro diagnostic testing </p></td> <td><p>Flagship Ventures, Polaris Venture Partners</p></td> <td><p>$10m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>SurgaColl Technologies</b></p></td> <td><p>Orthopaedics</p></td> <td><p>Tissue regeneration products. SurgaColl's first product is HydroxyColl, a bone graft substitute </p></td> <td><p>AIB Seed Capital Fund, Harmac Medical Products, Enterprise Ireland and private investors</p></td> <td><p>&euro;2m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>Svelte Medical Systems</b></p></td> <td><p>Cardiovascular</p></td> <td><p>Acrobat is a drug-eluting coronary stent</p></td> <td><p>Apjohn Ventures Fund, CNF Investments, Norwich Ventures and company founders</p></td> <td><p>$8m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>June</p></td> </tr> <tr> <td><p><b>EyeNetra</b></p></td> <td><p>Ophthalmology</p></td> <td><p>EyeNetra is developing a suite of cloud-based mobile eye diagnostic tests. </p></td> <td><p>Undisclosed</p></td> <td><p>$1m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Neuros Medical</b></p></td> <td><p>Neurology</p></td> <td><p>Neuros has initiated pilot trials in the US on it high-frequency Electrical Nerve Block technology for use in acute treatment of pain in the residual limb of amputees.</p></td> <td><p>Boston Scientific, Glengary, Case Tech Ventures, JumpStart Ventures, NorthCoast Angel Fund, Ohio Tech Angel Fund, Queen City Angel Fund III, Physician Investment Group RiverVest Venture Partners Blue Tree Allied Angels ModelVest </p></td> <td><p>$3.5m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Obalon Therapeutics</b></p></td> <td><p>Bariatric surgery</p></td> <td><p>Obalon has initiated a US clinical trial of its gastric balloon system. The device consists of a capsule containing a balloon that is swallowed and then remotely inflated. The balloon occupies space in the stomach to promote an artificial sense of fullness.</p></td> <td><p>InterWest Partners, Domain Associates, Okapi Venture Capital</p></td> <td><p>$16.5m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Valcare Medical</b></p></td> <td><p>Cardio/Peripheral vascular</p></td> <td><p>Valcare, a spinoff of MiCardia, is developing a transatheter mitral valve repair system</p></td> <td><p>Accelmed</p></td> <td><p>$8m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Avinger</b></p></td> <td><p>Cardiovascular imaging</p></td> <td><p>Avinger has just completed its CONNECT II global clinical trial of Ocelot, a crossing catheter with integrated real-time intravascular imaging, used for treating peripheral artery disease. The firm is also developing Wolverine, a peripheral atherectomy catheter with integrated intravascular imaging technology using optical coherence tomography.</p></td> <td><p>Undisclosed</p></td> <td><p>$33m</p></td> <td><p>Series D</p></td> <td><p>Around $80m</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>CartiHeal</b></p></td> <td><p>Regenerative medicine</p></td> <td><p>CartiHeal is developing implants for regeneration of cartilage and bone disorder. The firm's lead product is Agili-C is an arthroscopically-place implant used for repairing cartilage and osteochondral defects.</p></td> <td><p>Elron, Accelmed, Access Medical Ventures</p></td> <td><p>$10m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Lantos Technologies</b></p></td> <td><p>ENT</p></td> <td><p>Lantos has developed a 3D intra-aural digital scanner for dynamic imaging the ear canal. This helps to improve the fitting of hearing aids and other audio devices.</p></td> <td><p>Undisclosed</p></td> <td><p>$3.8m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Harmonic Cold Plasma</b></p></td> <td><p>Woundcare</p></td> <td><p>Harmomic's Wound Care Systems 1000  is developing a portable hand held device that converts a noble gas mixutre into a cold plasma state and delivers it to the site of a wound. This helps to eradicate potentially infectious bacteria, fungi and viruses, and can also accelerate the body's natural healing process at the cellular level.  </p></td> <td><p>Undisclosed</p></td> <td><p>$1m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Beacon Endoscopic</b></p></td> <td><p>Endoscopy/ Surgery</p></td> <td><p>Beacon's BNX system is a fine needle aspiration platform for use in endoscopic ultrasound and endoscopic bronchial ultrasound. </p></td> <td><p>Undisclosed</p></td> <td><p>$1.25m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>iWalk</b></p></td> <td><p>Bionic prosthetics</p></td> <td><p>iWalk develops bionic prosthetics to restore natural movement for lower-limb amputees. </p></td> <td><p>(from previous round) Sigma Partners, General Catalyst Partners, WFD Ventures</p></td> <td><p>$3.1m (debt financing)</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Clinithink</b></p></td> <td><p>Healthcare IT</p></td> <td><p>Clinithink's CLiX technology is a clinical language indexing software that structures the free text in electronic medical records.</p></td> <td><p>Vanguard Atlantic</p></td> <td><p>Undisclosed</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Cardiosolutions</b></p></td> <td><p>Cardio/peripheral vascular</p></td> <td><p>Cardiosolutions' lead product is a transcatheter-placed implantable device, the Mitra-Spacer, designed to treat moderate to severe mitral valve regurgitation </p></td> <td><p>Sorin</p></td> <td><p>$8m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Neuravi</b></p></td> <td><p>Cardio/Peripheral vascular</p></td> <td><p>Neuravi is developing a mechinical clot retrieval device, based on its Stent Basket technology, which will be used on acute ischaemic stroke patients. </p></td> <td><p>Fountain Healthcare Partners, Delta Partners</p></td> <td><p>&euro;5.2m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>IntegraGen</b></p></td> <td><p>IVD</p></td> <td><p>IntegraGen is developing molecular diagnostics for autism.</p></td> <td><p>A Plus Finance</p></td> <td><p>&euro;2m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Histogenics</b></p></td> <td><p>Regenerative medicine</p></td> <td><p>Histogenics is conducting Phase 3 trials of its NeoCart autologous neocartilage tissue implant.</p></td> <td><p>Sofinnova Ventures, Split Rock Partners, BioMed Ventures, FinTech GIMV Fund</p></td> <td><p>$49m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Allurion Technologies</b></p></td> <td><p>Bariatric surgery</p></td> <td><p>Allurion is developing a balloon device that is delivered in a pill which the patient swallows. The balloon expands in the stomach over several months and helps the patient feel full while consuming less food. </p></td> <td><p>Undisclosed</p></td> <td><p>$1.7m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Zonare Medical Systems</b></p></td> <td><p>Imaging</p></td> <td><p>Zonare commercialises diagnostic ultrasound devices, based on its zone sonography technology, used in different clinical applications</p></td> <td><p>Oxford Finance for current debt financing. Equity investors include Apposite Capital, Ascension Health, CB Health Ventures, Frazier Healthcare Ventures, Greenspring Associates, Mosaix Ventures, ePlanet Ventures, Texas Instruments, Earlybird</p></td> <td><p>$25 debt financing</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>July</p></td> </tr> <tr> <td><p><b>Intuity Medical</b></p></td> <td><p>Diabetes management</p></td> <td><p>The Pogo complete blood glucose monitoring system eliminates the need for separate testing supplies</p></td> <td><p>Undisclosed</p></td> <td><p>$12m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Retia Medical</b></p></td> <td><p>Patient monitoring</p></td> <td><p>Retia is developing a new, less-invasive system to monitor cardiac output (CO) and other key measures of the cardiovascular system accurately when patients go into shock.</p></td> <td><p>Pritzker/Vlock family office</p></td> <td><p>$7m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Medrobotics</b></p></td> <td><p>Surgery</p></td> <td><p>Medrobotics' robotic surgical products include the cardioARM, a robotic probe controlled remotely and designed to enable surgeries with minimal or no incisions. </p></td> <td><p>Eagle Ventures, The Pittsburgh Life Sciences Greenhourse and other investors</p></td> <td><p>$8m</p></td> <td><p>Series D</p></td> <td><p>$36.3m</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>EpiEP</b></p></td> <td><p>Surgery</p></td> <td><p>EpiEP has developed a system that provides cardiac surgeons with minimally invasive access to the epicardium, the outer layer heart tissue</p></td> <td><p>Conneticut Innovation, LaunchCapital and private investors</p></td> <td><p>$2.75m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Nuclea Biotechnologies</b></p></td> <td><p>IVD</p></td> <td><p>Nuclea is developing a suite of companion diagnostic assays  for use in therapeutic and medical imaging applications across the five major cancer types: colon, stomach, leukemia, lung and prostate. </p></td> <td><p>Undisclosed</p></td> <td><p>$5m</p></td> <td><p>Series C</p></td> <td><p>$35.9m</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Ikonisys</b></p></td> <td><p>IVD</p></td> <td><p>Ikonisys' portfolio of cell-based diagnostics incorporating its CellOptics platform for rare cell detection.</p></td> <td><p>Undisclosed</p></td> <td><p>$1.4m (converted debt to equity)</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Vayyar Imaging</b></p></td> <td><p>Imaging</p></td> <td><p>Vayyar is developing a processor that uses radiofrequency waves to image and detect breast cancer at an early stage.</p></td> <td><p>Battery Ventures, Bessemer Venture Partners, Israel Cleantech Ventures</p></td> <td><p>$12m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Ornim</b></p></td> <td><p>Patient monitoring</p></td> <td><p>Ornim's CE-marked and FDA-cleared CerOx noninvasively monitors blood flow and oxygen saturation in brain and muscle tissue. </p></td> <td><p>GE, OrbiMed Israel Partners, Agate-MAC Fund</p></td> <td><p>$20m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Sapheon</b></p></td> <td><p>Cardio/ Peripheral vascular</p></td> <td><p>The VenaSeal closure system is designed to treat venous reflux disease</p></td> <td><p>Undisclosed</p></td> <td><p>$8.6m</p></td> <td><p>First tranche of Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>CardioDx</b></p></td> <td><p>IVD</p></td> <td><p>CardioDx's Corus CAD is a gene expression test to identify symptomatic patients unlikely to develop obstructive coronary artery disease</p></td> <td><p>Temasek, Kleiner Perkins Caufield &amp; Byers, Mohr Davidow Ventures, TPG Biotech, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Group, GE Capital, Longitude Capital, JP Morgan, Acadia Woods Partners, Artiman Ventures, Bright Capital </p></td> <td><p>$58m</p></td> <td><p>Series F</p></td> <td><p>Over $175m</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Acutus Medical</b></p></td> <td><p>Cardiology</p></td> <td><p>Acutus is developing an electrophysiology diagnostics system to map cardiac arrhythmias</p></td> <td><p>Advent Life Sciences, Index Ventures, private investors</p></td> <td><p>$2.5m</p></td> <td><p>Expanded Series A</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Biodesix</b></p></td> <td><p>IVD</p></td> <td><p>Biodesix's first product is VeriStrat, a blood-based test to help personalise drug treatment for patients with non-small cell lung cancer</p></td> <td><p>Undisclosed</p></td> <td><p>$12m</p></td> <td><p>Expanded series D</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>VitaPath Genetics</b></p></td> <td><p>IVD</p></td> <td><p>VitaPath is focused on commercialising assays that test vitamin-remediable genetic variants. Its first test is a folate metabolism test to help assess a woman's preconception risk of having a spina bifida-affected pregnancy. </p></td> <td><p>Undisclosed</p></td> <td><p>$5m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>OmniGuide</b></p></td> <td><p>Surgery</p></td> <td><p>OmniGuide's BeamPath flexible CO2 laser system for minimally invasive surgery is used in gynaecology, ENT and neurosurgery. </p></td> <td><p>Stata Ventures, Psilos Group, ESI, Argonaut Ventures, Alliance Technology Ventures, Apposite Capital, Friday Street Ventures, Westbury Partners and OrbiMed Advisors </p></td> <td><p>$35m (non-dilutive growth financing from Orbimed only)</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Aug</p></td> </tr> <tr> <td><p><b>Mainstay Medical</b></p></td> <td><p>Orthopaedics</p></td> <td><p>Mainstay is developing a device for treating patients with chronic non-specific low  back pain.</p></td> <td><p>Fountain Healthcare Partners, Medtronic, Capricorn Venture Partners, Seventure Partners, Sofinnova Partners and Twin City Angels</p></td> <td><p>$20m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>IlluminOss Medical</b></p></td> <td><p>Orthopaedics</p></td> <td><p>IlluminOss's CE marked photodynamic bone stabilisation system is used to treat fractures in low load bearing bones. It incorporates a proprietary bone-filling liquid monomer that polymerises into a solid on exposure to a visible light source. </p></td> <td><p>Tekla Capital Management, Life Sciences Partners, Foundation Medical Partners, Mieza Capital, New Leaf Venture Partners, SR One, Excel Venture Management, Pappas Ventures, Slater Technology Fund</p></td> <td><p>$28m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Foundation Medicine</b></p></td> <td><p>IVD</p></td> <td><p>FoundationOne is a genomic assay for all solid tumours that identifies oncogenic alterations in the tumour to help tailor drug therapy for patients</p></td> <td><p>Deerfield Management Company, Casdin Capital, Redmile Group, Roche Venture Fund, WuXi Corporate Venture Fund, Kleiner Perkins Caufield &amp; Byers</p></td> <td><p>$42.5m </p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>ABT Molecular Imaging</b></p></td> <td><p>Diagnostic imaging</p></td> <td><p>ABT markets a generator which produces, at point of use, unit doses of molecular imaging drugs for positron emission tomography </p></td> <td><p>River Cities Capital Funds, Mountain Group Capital, Council Capital, Intersouth Partners</p></td> <td><p>$6m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>iWalk</b></p></td> <td><p>Orthopaedics</p></td> <td><p>iWalk manufactures personalised bionic foot and ankle systems</p></td> <td><p>Gilde Healthcare Partners, WFD Ventures, General Catalyst Partners, Sigma Partners </p></td> <td><p>$17m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Torax Medical</b></p></td> <td><p>Surgery</p></td> <td><p>Torax's FDA-approved LINX reflux management system is a surgical treatment for gastroesophageal reflux disease (GERD)</p></td> <td><p>Piper Jaffray Merchant Banking, Sanderling Ventures, Thomas McNerney &amp; Partners, Accuitive Medical Ventures, Kaiser Permanente, Mayo Medical Ventures</p></td> <td><p>$30m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>BioFire Diagnostics</b></p></td> <td><p>IVD</p></td> <td><p>BioFire develops rapid multiplex tests based on  its FilmArray diagnostic platform. It markest its respiratory panel, FilmArray, in the US and Europe and is developing other tests including blood culture identification, gastrointestinal and meningitis panels.</p></td> <td><p>Undisclosed</p></td> <td><p>$25m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Intact Vascular</b></p></td> <td><p>Cardio/ Peripheral vascular</p></td> <td><p>The Tack-It endovascular stapler device is desiged to optimise peripheral angioplasty results for treatment of peripheral artery disease. It is currently being trialled in Europe and expected to be CE marked end of 2012</p></td> <td><p>Quaker Partners, HIG BioVentures, angel investors</p></td> <td><p>$15.5m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>NeuWave Medical</b></p></td> <td><p>Surgery</p></td> <td><p>The Certus 140 microwave ablation system is FDA-cleared for the coagulation of soft tissue</p></td> <td><p>HIG BioVentures, Venture Investors, WARF, State of Wisconsin Investment Board</p></td> <td><p>$14m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Apnex Medical</b></p></td> <td><p>Neurology</p></td> <td><p>Apnex's implantable Hypoglossal Nerve Stimulation System electrically stimulates the muscles that control breathing to treat patients with obstructive sleep apnoea. The device is underoing clinical trials.</p></td> <td><p>New Enterprise Associates, Domain Associates, Polaris Venture Partners, Michael Berman</p></td> <td><p>$10m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Exagen Diagnostics</b></p></td> <td><p>IVD</p></td> <td><p>Exagen specialises in tests for rheumatologic disorders. It commercialises Avise SLE for testing systemic lupus erythematosus, Avise PG to measure how well the body metabolises methotrexate (a treatment for rheumatoid arthritis) and Avise MCV, for diagnosing rheumatoid arthritis.</p></td> <td><p>Tullis Health Investors, Sun Mountain Capital, Cottonwood Technology Fund, Mesa Verde Venture Partners, Epic Ventures</p></td> <td><p>$5.3m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Tandem Diabetes Care</b></p></td> <td><p>Diabetes management</p></td> <td><p>Tandem's FDA-cleared t:slim insulin delivery system is a pocket-sized full-featured insulin pump with a colour touch screen.  </p></td> <td><p>Undisclosed</p></td> <td><p>$36.4m</p></td> <td><p>Undisclosed</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Provista Diagnostics</b></p></td> <td><p>IVD</p></td> <td><p>Provista is completing confirmatory clinical trials for its dtectDx-Breast blood test. The product is used in conjunction with mammography to help early detection of breast cancer. </p></td> <td><p>Undisclosed</p></td> <td><p>$2.5m</p></td> <td><p>Second tranche of Series A</p></td> <td><p>$7.5m</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Aushon BioSystems</b></p></td> <td><p>IVD</p></td> <td><p>The Cira immunoassay platform is designed to perform multiplex analysis with the affordability, sensitivity and consistency of singleplex ELISA, but 25 times faster and using 23 times less material.</p></td> <td><p>Undisclosed</p></td> <td><p>$5.5m</p></td> <td><p>Undisclosed</p></td> <td><p>$24m</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Bio2 Medical </b></p></td> <td><p>Cardio/ peripheral vascular</p></td> <td><p>The Angel catheter, named after its inventor and Bio2's chief medical officer Dr Luis Angel, is a central venous catheter and inferior vena cava filter combination device for protection against pulmonary embolism.</p></td> <td><p>Incyte Ventures Targeted Technology Fund, Remeditex Ventures</p></td> <td><p>$12m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>Sept</p></td> </tr> <tr> <td><p><b>Verax Biomedical</b></p></td> <td><p>IVD</p></td> <td><p>Verax's Platelet PGD Test is a rapid diagnostic for detecting bacterial contamination in blood platelets hours before transfusion. The FDA-cleared test is based on the company's Pan Genera Detection technology. </p></td> <td><p>Undisclosed</p></td> <td><p>$3.3m </p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Biom'Up</b></p></td> <td><p>Regenerative medicine/ Surgery</p></td> <td><p>Biom'Up is already commercialising 1)COVA, a membrane used in surgery to prevent adhesions and controlled healing, in the EU and US and 2)MATRI BONE, a bone regeneration matrix, in the EU</p></td> <td><p>CDC Enterprises/InnoBio, Viveris Management, OTC Asset Management, Merieux Developpement, SHAM, Sofimac Partners, Aquasourca, L'Ameliane and Biom'Up's founders</p></td> <td><p>&euro;6.8m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Quantason</b></p></td> <td><p>Imaging</p></td> <td><p>Quantason is completing the development of its Idus biomodal ultrasound technology, designed for visualising breast premalignant lesions, such as clusters and grouped microcalcifications. </p></td> <td><p>Private investors</p></td> <td><p>$3.2m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Spinal Restoration</b></p></td> <td><p>Regenerative medicine </p></td> <td><p>The Biostat System is an intradiscal biologic therapy for discogenic low back pain. It consists of the Biologx fibrin sealant, a human-derived resorbable biologic tissue sealant which is delivered to the intervertebral disc via the Biostat delivery device.</p></td> <td><p>Austin Ventures Sante Ventures and MB Ventures </p></td> <td><p>$3m (plus $2m debt financing from Comerica Bank)</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Nanostim</b></p></td> <td><p>Cardiology</p></td> <td><p>Nanostim is developed miniaturised, leadless pacemakers.</p></td> <td><p>St Jude Medical, InterWest Partners, US Venture Partners, Emergent Medical Partners, Life Sciences Angels and other private investors</p></td> <td><p>$10m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Cibiem</b></p></td> <td><p>Neurology</p></td> <td><p>Cibiem using a proprietary Carotid Body Modulation (CBM) approach to treat sympathetic nervous system-mediated diseases such as hypertention, heart failure, diabetes and renal failure. The firm is already in first-in-man clinical trials.</p></td> <td><p>SV Life Sciences, Third Rock Ventures</p></td> <td><p>$10m</p></td> <td><p>Series A</p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Lanx</b></p></td> <td><p>Orthopaedics</p></td> <td><p>Lanx is focused on minimally invasive spinal surgical products and is commercialising a wide range of devices and fusion systems.</p></td> <td><p>Undisclosed</p></td> <td><p>$8.7m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>BiOxyDyn</b></p></td> <td><p>Imaging</p></td> <td><p>BiOxyDyn is developing diagnostic imaging solutions for lung disease, with particular application in chronic obstructive pulmonary disorder and asthma. The company also provides quantitative medical imaging services to the pharmaceutical industry.</p></td> <td><p>The North West Fund for Biomedical, UMIP Premier Fund</p></td> <td><p>&pound;1.2m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Definiens</b></p></td> <td><p>Digital pathology</p></td> <td><p>Definiens has developed the Cognition Network Technology used for image analysis in digital pathology. The technology is used for R&amp;D purposes by pharma companies and an increasing number of diagnostic companies in tissue-based diagnostic biomarker development.</p></td> <td><p>Gilde Healthcare Partners, TVM, Cipio and Definiens' management</p></td> <td><p>&euro;10m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>LoneStar Heart</b></p></td> <td><p>Regenerative medicine/ Cardiology</p></td> <td><p>LoneStar has developed the Algisyl0LVR, a biopolymer that is injected into the heart's left ventricle during surgery and remain in the heart muscle as permanent implants to support the injured heart, reducing the ventricle's tension and stress</p></td> <td><p>Themes Investment Partners and others</p></td> <td><p>Up to $20m (includes milestones)</p></td> <td><p>Undisclosed </p></td> <td><p>Up to $35m</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>EyeBrain</b></p></td> <td><p>Neurology</p></td> <td><p>EyeBrain is developing brain function markers for neurological and psychiatric diseases using its Mobile EyeBrain Tracker that records and analyses eye movements.</p></td> <td><p>Octalfa, Sudinnova, CM-CIC Capital Innovation, CapDecisif Management, G1JIDF</p></td> <td><p>&euro;3.3m</p></td> <td><p>Series B</p></td> <td><p>&euro;4.5m</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>BioBehavioral Diagnostics</b></p></td> <td><p>Neurology</p></td> <td><p>BioBehavioral has developed the Quotient ADHD test system. The device measures a person's ability to think by assessing motion and attention state, thereby providing data on hyperacitivity, impulsivity and inattention.</p></td> <td><p>Undisclosed</p></td> <td><p>$2.5m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>GnuBIO</b></p></td> <td><p>IVD</p></td> <td><p>GnuBIO will be commercialising in 2013 its desktop system for performing targeted and whole genmoe sequencing. The entire process is all on the chip and the results ready in hours. </p></td> <td><p>Private investors</p></td> <td><p>$10m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Tactile Systems Technology</b></p></td> <td><p>Chronic disease management</p></td> <td><p>Tactile's Flexitouch system is designed for at-home treatment of lymphedema, chronic ediema and non-healing venous ulcers</p></td> <td><p>Galen Partners and private investors</p></td> <td><p>$10.4m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>OptiScan Biomedical</b></p></td> <td><p>Patient monitoring</p></td> <td><p>The OptiScanner is a continuous glucose monitoring system designed for use in the intensive care unit.</p></td> <td><p>Undisclosed</p></td> <td><p>$5.1m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>Trivitron Healthcare</b></p></td> <td><p>Medical devices distribution</p></td> <td><p>Trivitron is India's largest wholesale distributor and after-sales support provider of medical equipment and devices. It specialises in imaging, lab diagnostics, cardiology, critical care, renal care, operating room and ophrhalmology equipment. </p></td> <td><p>Fidelity Growth Partners India</p></td> <td><p>INR400 crores ($75m) </p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Oct</p></td> </tr> <tr> <td><p><b>CardiAQ Valve Technologies</b></p></td> <td><p>Cardiology</p></td> <td><p>CardiAQ is developing a proprietary system for transcatheter mitral valve implantation. </p></td> <td><p>Orbimed, Versant Ventures, Advent Life Sciences and private investors</p></td> <td><p>$37.3m</p></td> <td><p>Series B</p></td> <td><p>$43.8m</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>Endosense</b></p></td> <td><p>Cardiology</p></td> <td><p>Endosense has CE-marked and is commercialising its TactiCath force-sensing catheter ablation technology, used to treat cardiac arrhythmias. It is completing US trials of its technology to gain FDA approval.</p></td> <td><p>NGN Capital, Edmond de Rothschild Investment Partners, NeoMed Management, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie and private investors</p></td> <td><p>$40.3m</p></td> <td><p>Series C</p></td> <td><p>$96.3m</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>GlySure</b></p></td> <td><p>Patient monitoring</p></td> <td><p>Glysure has developed a continuous blood glucose monitoring ystems for use in the intensive care unit in hospitals. </p></td> <td><p>Amadeus Capital Partners, Chester Investments, Delta Partners, Morningside Ventures and private investors</p></td> <td><p>$13.6m</p></td> <td><p>Series C-2</p></td> <td><p>$22.4m</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>EarlySense</b></p></td> <td><p>Patient monitoring</p></td> <td><p>EarlySense has developed a non-contact system that continuously monitors a patient's vital signs and movement using a sensor that is placed underneath a bed mattress. There are no leads , cuffs or attachements connected to the patient, who is allowed complete freedom of movement.</p></td> <td><p>Pitango Venture Capital, JK&amp;B, ProSeed VC Fund, Docor International Management, Bridge Investment Fund</p></td> <td><p>$15m</p></td> <td><p>Series E</p></td> <td><p>Undisclosed</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>Epic Sciences</b></p></td> <td><p>IVD</p></td> <td><p>Epic is developing diagnostic tests that can detect and profile biomarkers on circulating tumour cells in the blood, to provide a noninvasive method of detecting cancer and monitoring and personalising cancer drug treatments.</p></td> <td><p>Domain Associates, Roche Venture Fund, Pfizer Venture Investments and private investors</p></td> <td><p>$13m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>Quanterix</b></p></td> <td><p>IVD</p></td> <td><p>Quanterix's Simoa multiplex immunoassay technology is based on a digital approach that enables detection of a signal from single molecules of a labelled analyte, and is much more sensitive than conventional analog-based protein detection technologies.</p></td> <td><p>bioMerieux, ARCH Venture Partners, Bain Capital Ventures, Flagship Ventures and In-Q-Tel</p></td> <td><p>$18.5m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>Metamark Genetics</b></p></td> <td><p>IVD</p></td> <td><p>MetaMark is developing two prostate cancer prognostic tests. The first is a tissue-based test to determine whether the cancer is a slow-growing or aggressive form, and the second predicts the longer-term course of disease.</p></td> <td><p>Private investors</p></td> <td><p>$13m</p></td> <td><p>Series B</p></td> <td><p>Around $43m</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>Seno Medical Instruments </b></p></td> <td><p>Imaging</p></td> <td><p>Seno has developed an opto-acoustic imaging technology for detecting breast cancer.</p></td> <td><p>Undisclosed</p></td> <td><p>$14.5m of a larger $21m round</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>TriReme Medical</b></p></td> <td><p>Cardio-/ Peripheral Vascular</p></td> <td><p>TriReme specialises in balloon catheters for treating complex coronary and peripheral vascular disease.</p></td> <td><p>Luminor Capital, Bio*One Capital, Three Arch Partners and Adams Street Partners</p></td> <td><p>$18m</p></td> <td><p>Series E</p></td> <td><p>Undisclosed</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>Tangent Medical Technologies</b></p></td> <td><p>Vascular access</p></td> <td><p>Tangent has developed NovaCath, an FDA-cleared closed-system IV device. </p></td> <td><p>Undisclosed</p></td> <td><p>$8.6m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>NICO</b></p></td> <td><p>Surgery</p></td> <td><p>Myriad, NICO's lead device, is an automated non-heat-generating surgical tool for removing damaged tissue from the brain and spine.</p></td> <td><p>Rose-Hulman Institute of Technology, River Cities Capital Fund, CHV Capital, Cornelius Private Investments and Twilight Venture Partners</p></td> <td><p>$6.5m</p></td> <td><p>Undisclosed </p></td> <td><p>Over $20m</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>iRhythm Technologies</b></p></td> <td><p>Cardiology</p></td> <td><p>iRhythm's Zio Patch is a single-use, water-resistant continuous cardiac rhythm monitoring device that can be worn for up to 14 days. It is used for early diagnosis of cardiac arrhythmia.</p></td> <td><p>Undisclosed</p></td> <td><p>$3.5m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>OptiMedica</b></p></td> <td><p>Ophthalmology</p></td> <td><p>OptiMedica is commercialising its FDA-cleared and CE-marked Catalys Precision Laser System for performing cataract surgery.</p></td> <td><p>Kleiner Perkins Caufield &amp; Byers, Alloy Ventures, DAG Ventures, BlackRock Private Equity Partners and Bio*One Capital </p></td> <td><p>$35m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>Advanced Cell Diagnostics</b></p></td> <td><p>IVD</p></td> <td><p>ACD develops cell- and tissue-based diagnostic tests for personalised medicine, based on its proprietary RNAscope technology.</p></td> <td><p>New Leaf Venture Partners, Morningside Ventures</p></td> <td><p>$12m</p></td> <td><p>Series B</p></td> <td><p>$17.4m</p></td> <td><p>Nov</p></td> </tr> <tr> <td><p><b>Ignyta</b></p></td> <td><p>IVD</p></td> <td><p>Ignyta is initiating in 2013 clinical trials of its Enlyta molecular assays  for diagnosing rheumatoid arthritis at its earliest, most treatable stages</p></td> <td><p>Colt Ventures, City Hill Ventures, private investors</p></td> <td><p>$3.4m</p></td> <td><p>Series B-2</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Magenta Medical</b></p></td> <td><p>Cardiology</p></td> <td><p>Magenta is an early-stage start-up developing medical device for treating acute and chornic heart failure.</p></td> <td><p>Pitango Venture Capital</p></td> <td><p>$4m</p></td> <td><p>Seed</p></td> <td><p>n/a</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Cardiosonic </b></p></td> <td><p>Neurology</p></td> <td><p>Cardiosonic's TIVUS catheter-based system uses high-intensity, non-focused ultrasound energy to perform remote renal denervation to treat hypertension, without damaging the arterial endothelium. </p></td> <td><p>Private investors</p></td> <td><p>$6.1m</p></td> <td><p>Series B-1</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Kona Medical</b></p></td> <td><p>Neurology</p></td> <td><p>Kona is conducting clinical trials of Surround Sound, its fully noninvasive system that delivers ultraound outside the body to ablate renal nerves to treat hypertension.</p></td> <td><p>Unnamed large-cap strategic investors, Essex Woodlands, Domain Associates, Morgenthaler Ventures, Western Technology Investments, BioStar Ventures</p></td> <td><p>$40m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Nanostring Technologies</b></p></td> <td><p>IVD</p></td> <td><p>Nanostring provides a gene profiling service, using its nCounter analysis system, for life sciences research applications; it has also developed its first molecular diagnostic product, a breast cancer assay based on the PAM50 gene expression signature.</p></td> <td><p>Morgan Stanley Expansion Capital, Alliance Bernstein Alternative Investment Management Group, Clarus Ventures, Draper Fisher Jurvetson, OVP Venture Partners, GE healthymagination Fund, BioMed Ventures, Henri Termeer</p></td> <td><p>$15.3m</p></td> <td><p>Series E</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Avelas Biosciences</b></p></td> <td><p>Imaging</p></td> <td><p>The Avelas Cancer Illuminator (ACI) allows real-time visualisation of metastatic nodes to allow surgeons to remove additional nodes during the first surgery, and eliminate the need for the patient to undergo a subsequent surgical procedure. </p></td> <td><p>Avalon Ventures</p></td> <td><p>$7.65m</p></td> <td><p>Series A</p></td> <td><p>n/a</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Innovative Trauma Care (ITC)</b></p></td> <td><p>Wound management</p></td> <td><p>The ITClamp haemorrhage control system is designed to control rapidly critical bleeding. It is approved for sale in Canada, and ITC expects to CE mark and gain FDA clearance in 2013.</p></td> <td><p>Undisclosed</p></td> <td><p>$3.6m</p></td> <td><p>Series A</p></td> <td><p>n/a</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Biocartis</b></p></td> <td><p>IVD</p></td> <td><p>BioCartis's Apollo rapid and fully-automated molecular diagnostics platform was acquired from Philips in 2010. The company is now developing a medu of oncology tests to run on the system.</p></td> <td><p>PMV, RMM Valiance, Debiopharm Group, Korys, Philips, J&amp;J Development Corp, family office of Dr Paul Janssen, Luc Verelst, Benaruca, New Rhein Healthcare</p></td> <td><p>&euro;34.5m</p></td> <td><p>Series D</p></td> <td><p>&euro;145.5m</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Angel Medical Systems</b></p></td> <td><p>Cardiology</p></td> <td><p>The CE-marked AngelMed Guardian system is an implantable cardiac device designed to continuously monitor the patient's heart signals, detect changes that may indicate the onset of a heart attack and alert the patient to seek medical attention.</p></td> <td><p>SOAM Angel Partners and other VC, strategic and angel investors</p></td> <td><p>$27.5m </p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Sharklet Technologies</b></p></td> <td><p>Surface technology</p></td> <td><p>Sharklet has developed a bacteria-inhibiting microtexture surface technology that can be incorporated into medical devices  - such as endotracheal tube and central venous catheter - that potentially act as a conduit for bacteria to enter the body. </p></td> <td><p>Altria Ventures</p></td> <td><p>$2m</p></td> <td><p>Undisclosed </p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Cerapedics </b></p></td> <td><p>Regenerative medicine/ Orthopaedics </p></td> <td><p>Cerapedics' CE-marked i-FACTOR bone graft is said to be the only biologic bone graft that uses a synthetic small peptide as an attachment factor to stimulate the natural bone healing process, at a fraction of the cost of biologic growth factors.</p></td> <td><p>MedImmune Ventures, CVF, OrbiMed Advisors, NGN Capital</p></td> <td><p>$19m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>DioGenix</b></p></td> <td><p>IVD</p></td> <td><p>DioGenix is clinically validating MSPreciseits next-generation gene sequencing test for the early identification and diagnosis of multiple sclerosis </p></td> <td><p>Nervada</p></td> <td><p>$1.5m</p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Ortho Kinematics</b></p></td> <td><p>Orthopaedics</p></td> <td><p>Ortho Kinematics specialises in spine imaging informatics, Its proprietary VMA (vertebral motion analysis) technology provides spine biomechanical data to help improve the diagnosis and treatment of back pain. </p></td> <td><p>Texo Ventures, PTV Sciences, Gatebridge Investments, Texas Emerging Technology Fund </p></td> <td><p>$2m</p></td> <td><p>Series B</p></td> <td><p>$7.5m</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Medrobotics</b></p></td> <td><p>Surgery</p></td> <td><p>Medrobotics' Flex robotic system enables surgeons to gain single-site access and visualisation to difficult-to-access anatomical structures.</p></td> <td><p>Undisclosed</p></td> <td><p>$33.6m</p></td> <td><p>Series D</p></td> <td><p>$62m</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>SurgiQuest</b></p></td> <td><p>Surgery</p></td> <td><p>SurgiQuest develops devices for use in laparascopic procedures. Its portfolio includes  AirSeal, a valve-free trocar, and AnchorPort, a self-adjusting and self-anchoring trocar.</p></td> <td><p><escenic_non_breaking_space></escenic_non_breaking_space></p></td> <td><p>$7.5m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>SynapDx</b></p></td> <td><p>IVD</p></td> <td><p>SynapDx is developing a blood-based diagnostic test for autism spectrum disorders, which would identify children with the condition by age 36 months.</p></td> <td><p>North Bridge Venture Partners, General Catalyst Partners, Bain Capital Ventures</p></td> <td><p>$6m</p></td> <td><p>Series B </p></td> <td><p>$15m</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>InSightec</b></p></td> <td><p>Imaging</p></td> <td><p>InSightec's ExAblate platform combines MRI to visualise the target tissue or tumour and high-intensity focused ultrasound to ablate the target noninvasively. The technology is CE marked and FDA-approved for treating uterine fibroids, CE-marked for pain palliation of bone metasteses and being clinically assessed for other applications.</p></td> <td><p>GE Healthcare, Elbit Imaging, MediTech Advisors and other private investors</p></td> <td><p>$30.9m</p></td> <td><p>Series C</p></td> <td><p>$75.9m</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>Wright Therapy Products</b></p></td> <td><p>Chronic disease management</p></td> <td><p>Wright markets home-use compression therapy devices for the management of lymphedema, venous insufficiency and also for use in the sports medicine markets.</p></td> <td><p>Undisclosed</p></td> <td><p>$3m </p></td> <td><p>Series B</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>MC10</b></p></td> <td><p>Electronics</p></td> <td><p>MC10 specialises in conformal electronics that stretch and bend seamlessly with the body's movements. The technology's medtech applications include making 'smart' interventional catheters that provide enhanced feedback to electrophysiologists and also for making 'smart' surgical sutures that can monitor wound healing.</p></td> <td><p>Medtronic and other strategic investors</p></td> <td><p>$10m</p></td> <td><p>Series C</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> <tr> <td><p><b>23andMe</b></p></td> <td><p>IVD</p></td> <td><p>23andMe uses DNA anaysis technologies and web-based interactive tools to provide a Personal Genome Service ie personalised genetic research, to help individuals gain insight into inherited health traits.</p></td> <td><p>Private investors, Google Ventures, New Enterprise Associates, MPM Capital</p></td> <td><p>$50m</p></td> <td><p>Series D</p></td> <td><p>Undisclosed</p></td> <td><p>Dec</p></td> </tr> </table>  </p> 
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 15

VC Funding 2012
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20160622T191409
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT061234
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 15

VC Funding 2012
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

339119
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T191617Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

bd2e500a-e7be-40d3-9649-40593e2ad062
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T231409Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 14

sitecore\admin
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
